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MASS SPECTROMETRY STUDIES OF IMMUNOGLOBULINS 
YANYAN LU 
Boston University School of Medicine, 2015 





 Immunoglobulin (Ig) proteins, also known as antibodies, are important molecules 
with great variability in their amino acid sequences. Aberrantly overproduced 
monoclonal Ig light chain (LC) proteins may aggregate into a β-sheet featured structure, 
and deposit in the extracellular space; this pathologic process, called primary amyloidosis 
or Ig LC amyloidosis (AL) causes problems to multiple organs during the course of the 
disease. Post-translational modifications (PTMs), which remain to be explored, are likely 
an important factor affecting the formation of AL fibrils. In addition, therapeutic 
monoclonal antibodies (mAbs) are widely employed because of their high specificity and 
low side effects. Using plants as the expression platform is commercially attractive 
although this approach has been hampered by low protein expression yield and undesired 
glycosylation patterns. 
The investigations detailed in this dissertation focus on the analyses of Ig proteins 
derived from several human and plant sources. A method combining 2D SDS-PAGE 
separation and mass spectrometry (MS) analysis was used for de novo sequencing of Ig in 
a fat biopsy for which the corresponding DNA was unavailable, and for characterizing 
the LC proteins found in autopsied kidney, serum and urine samples from patients with 
  viii 
AL amyloidosis whose LC-DNA was sequenced. The PTMs of each LC were extensively 
characterized with different enzymes and various tandem MS techniques including 
collision-induced dissociation (CID), higher-energy collisional dissociation (HCD) and 
electron transfer dissociation (ECD). PTMs observed include truncations, mono-/di-
chlorination of the tyrosine residues and a nitrile group formed from the primary amine 
on lysine side chains. All these may play critical roles in the fibrillogenesis and/or the 
disease pathogenesis. Experimental evidence supports the hypothesis that the proteolytic 
processing of amyloidogenic LCs occurs after deposition in the organ. 
Characterization of a plant-derived HSV8 mAb was accomplished using high-
performance liquid chromatography separation and gel display followed by various MS 
methods. Three N-terminal and one C-terminal truncations were found. The N-glycan 
moiety attached to the heavy chain was also analyzed. The MS method established helps 
to elucidate important structural information on therapeutic mAbs in complex mixtures, 
potentially contributing to optimization of plant systems that may produce more stable 
mAbs. 
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Introduction and Literature Review  
 
1.1 Immunoglobulin Proteins 
Immunoglobulin (Ig) proteins, commonly known as antibodies, are large 
glycoproteins produced by B cells in membrane-bound and secreted forms. They are key 
components of the humoral immune system protecting against invading antigens.  
 
1.1.1 Structures and Functions 
In humans, there are five isotypes or classes of Igs differentiated by the heavy 
chain (HC) constant (C) domain sequences; these are IgG, IgA, IgM, IgD and IgE, listed 
in decreasing order of serum concentrations 
(1)
. Some basic properties of the five isotypes 
are summarized in Table 1.1. For IgG, there are four subclasses, each with a distinctive 
disulfide bond pattern 
(2)
. Two subclasses of IgA have been described; unlike IgA1 which 
contains disulfide linked HC and light chain (LC), IgA2 features noncovalent bonding 
between the polypeptide chains 
(3)
. Secreted IgA is dimerized, while IgM, although 
expressed as a monomer on the B cell surface, is present as a pentamer in the secreted 
form. In addition to structural variations, the Ig types differ in distributions over the body 
and effector functions. They work differently and cooperatively against various antigens 
(1)
. Among the immunoglobulins, IgG is the most abundant in the serum (mean adult 
value for IgG1 is 9 mg/mL) and the most extensively studied 
(1, 4-6)




recruited upon exposure to antigens. IgA, although present in serum at low concentrations 
(mean adult value for IgA1 is 3 mg/mL) is the dominant Ig class in the secretions, for 
example saliva sweat, tears and colostrum. It is responsible for mucosal response 
(3)
. IgD 
is usually co-expressed with IgM on mature B cell membranes 
(7)
. IgE is responsible for 
allergic reactions. 
 
Table 1.1 Properties of human Ig isotypes. 




































IgM  μ 1.5 Pentamer Yes 
IgD  δ 0.03 Monomer No 
IgE  ε 0.00005 Monomer No 




The Ig monomer is composed of two HCs and two LCs, which form a Y-shaped 
structure (Figure 1.1) 
(6)




proteins, kappa (κ) and lambda (λ), which are encoded by gene clusters on different 
chromosomes 
(8, 9)
. Kappa and lambda LCs do not show differences in functions. An 
individual Ig molecule has two identical copies of either a κ or λ LC; mixed LC types on 
an Ig protein do not occur naturally 
(1, 6)
. HCs are encoded by a multigene family that is 
separate from LCs 
(10, 11)
. There are five classes of HC proteins which are categorized by 
amino acid sequence, μ (IgM), γ (IgG), α (IgA), ε (IgE) and δ (IgD). In an Ig molecule, 
each of the four polypeptide chains contains an N-terminal variable sequence domain 
(V), joining region (J), and a constant sequence domain (C). In the LC there is one V 
region (VL) and one C domain (CL), while in the HC there is one V region (VH) and three 
C domains (CH1, CH2, CH3). The VL and VH regions of one LC and one HC pair with 
each other and form the part of an Ig molecule which recognizes and binds antigens. An 
interchain disulfide bond between the CL and CH1 domains is key in maintaining the 
antigen-binding structure of the Ig and facilitates antigen binding. The CH2 and CH3 
domains of the HC show another function of the Ig, namely the ability to bind specific 
effectors which lead to clearance of the pathogens. For IgG, there is a hinge region, 
between CH1 and CH2, where the structure is quite flexible. Two enzymes, papain and 
pepsin, are commonly used to cleave Ig proteins at HC sites within and outside of the 
hinge region, respectively 
(12, 13)
. Papain cleavage of Ig generates two antigen-binding 
(Fab) fragments and single crystallizable (Fc) fragment; pepsin digestion of Ig occurs at 
the C-terminal side of the protein beyond the hinge region and yields a cross-linked 











The human body is capable of producing a broad pool of Igs to fight against a 
large repertoire of antigens in part due to the primary structure diversity of VL and VH 
domains. The V region sequences are further divided into four framework regions (FRs) 
and three complementarity determining regions (CDRs) or hypervariable regions (HVs). 
The FRs have relatively conserved sequences and serve as a scaffold for Ig structure. The 
CDR or HV domains, which form a variety of loop structures from a diversity of 
sequences, determine the antigen binding affinity and specificity of the Ig. 
The wide variety of amino acid sequences in CDR regions originates at the gene 
level. Each polypeptide Ig domain is encoded by a distinct group of genes. For the VL 
and VH domains, separate clusters of V(D)J germline gene segments are used. There are 







. A step called V(D)J rearrangement, which precedes gene 
transcription, helps create random combinations of V(D)J genes 
(1, 15)
. HC proteins are 
derived from 39 functional V genes, 27 functional D genes and 6 functional J genes; 




. In addition, 
Ig sequence diversity also results from modifications present in D genes and 
rearrangement alterations due to nucleotide addition, terminal nucleotide removal, and 
the random insertion of non-germline-encoded nucleotides. When all these factors are 
taken into account, more than 10
16 
different Igs can be generated under pre-immune 
conditions. Upon exposure to antigens, a further step called somatic hypermutation helps 
to produce tailored Igs by introducing nucleotide mutations or nucleotide mismatches in 
the V domain genes 
(18-24)
. 
For the CL domain, κ and λ LC genes have one and four functional exons, 
respectively. The CH region has nine functional genes 
(8)
. In an immune response, through 
a process called class-switch recombination, each CH can associate with any VH created 




Igs are glycoproteins containing mainly N-linked glycans; O-linked glycans are 
found in human IgD and IgA1 only 
(25)
. N-glycosylation occurs when glycans are linked 
to the side chain amino group of an asparagine residue found in the motif N-X-S/T, 
where X≠P (26). O-glycans attach to the side chain hydroxyl groups of serine and 
threonine. Each Ig isotype has its own glycosylation pattern which greatly influences the 
structure and thus, the function of the protein 
(25, 27-30)




regardless of the subtype, has one conserved N-glycosylation site at Asn 297 of the HC in 
the CH2 domain 
(31-33)
. The two attached N-glycans stabilize the Fc region and also the 
overall three dimensional (3D) conformation of the IgG protein. 
IgG possesses two types of effector functions to clear antigens. One is the 
antibody-dependent cellular cytotoxicity (ADCC) and the other is the complement-
dependent cytotoxicity (CDC) 
(34, 35)
. ADCC relies on binding of the Fc region of an 
antibody to Fc receptors on an effector cell surface. Shields et al. cultivated an IgG1 
monoclonal antibody (mAb) in Lec13 cells, a variant of the Chinese hamster ovary 
(CHO) cell line, which could perform glycosylation similar to that of the wild-type CHO 
cells and also the human body while lacking the ability to add core α1,6-fucose (36). The 
mAb had improved binding to human Fc receptor, FcγRIIIa, and enhanced the ADCC 
effect, while there was no change of binding to the C1q complex and CDC. Similarly, 
Forthal et al. removed α1,3-fucose and xylose from 2G12, a mAb derived from plants, 
leading to a higher anti-HIV activity through enhanced FcγRIIIa binding and ADCC (37). 
CDC works through recruiting C1q complexes to the Fc region, which can be also altered 
by the glycan content in the Fc region. A cell line called Lec 1, also derived from CHO 
which lacks N-acetylglucosaminyltransferase I activity, produces IgG1 incapable of C1q 
binding and CDC 
(29)
. 
Glycosylation of V domain residues is also possible, and will then influence the 
antigen binding either positively or negatively 
(25, 28, 30)
. Antigen binding may be blocked 




Igs are a new and important class of therapeutic biomolecules. Intact IgG and 
antibody fragments, including Fab and single chain antigen binding regions like scFv (a 
fusion protein of VL and VH), are being adopted for use as immunotherapy agents 
(38-40)
.  
Compared with small molecule drugs, these immunotherapeutic agents should have 
greater binding specificity and efficiency resulting in fewer side effects. Antibody drugs 
can be used as a treatment for patients who have developed certain diseases or as a 
preventive method in people after exposure to specific pathogens. 
Administration of mAbs offers passive immunotherapy, an approach that differs 
from active immunization provoked by vaccines. The latter typically requires weeks to 
months and participation by the immune system to provide protection. Passive 
immunization is an immediate remedy with more predictable pharmacokinetics. 
Therapeutic mAbs can be especially helpful for people with compromised immune 
systems. Since approval of the first mAb (orthoclone OKT3) in 1986, more than 30 
antibody-based agents have been approved by the U.S. Food and Drug Administration 
(FDA) for use as medical treatments and a large number of antibody drugs are currently 
being studied in clinical trials. 
 
1.1.2 Immunoglobulin Light Chain Amyloidosis 
 Amyloidosis is a disease that occurs when normally soluble proteins aggregate 
into an organized β-sheet structure and deposit in the extracellular space of tissues. The 









body, in contrast to the Alzheimer’s disease, which features localized amyloid deposits in 
the brain 
(45-47)
. So far, more than 20 proteins, of wild-type or variant form, have been 
identified as the major protein constituent of deposited amyloid fibrils (Table 1.2) 
(48, 49)
. 
Among these diseases, immunoglobulin light chain amyloidosis (AL), also known as 
primary (systemic) amyloidosis, is reported to be the most common type of systemic 
amyloidosis in America 
(50)
. Amyloid aggregates of Ig LCs deposit in tissues and organs 
far from the site where the LCs are produced, i.e. plasma cells in the bone marrow. The 
organs most frequently involved in AL amyloidosis include heart, kidney and liver, and 
consequently survival time from onset of disease is typically short, i.e. < 18 months 
(51, 
52)
. Patients with this disease have a plasma cell dyscrasia demonstrated by the presence 
of monoclonal plasma cells in the bone marrow. The diagnosis of AL amyloidosis relies 
on histologic confirmation of amyloid usually with Congo red and immunochemical or 
biochemical identification of LC as the amyloid protein in the deposits. Clinical testing 
also includes quantitative measurements of the bound and free monoclonal LCs found in 
patient serum and urine samples.  
 Amyloidosis caused by Ig HC proteins has also been reported although this 










Table 1.2 Amyloidogenic precursor proteins associated with systemic amyloidosis. 
(adapted from reference 
(48)
) 
Amyloid Precursor Amyloid Designation 
Immunoglobulin light chain AL 
Immunoglobulin heavy chain AH 
Transthyretin (wild-type) ATTRwt 
Transthyretin (mutants > 100) ATTRm 
Serum amyloid A AA 
Apolipoprotein AI (wild-type) AApoAI 
Apolipoprotein AI (variants ≥ 12) AApoAI 
Apolipoprotein AII (variants ≥ 2) AApoAII 
Apolipoprotein AIV (wild-type) AApoAIV 
Beta 2-microglobulin Aβ2M 
Lysozyme (variants > 4) ALys 
Fibrinogen Aα-Chain (variants > 4) AFib 
Gelsolin (variants ≥ 4) AGel 
Calcitonin ACal 
Islet amyloid polypeptide AIAPP 
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Fibrillogenesis factors  
To expand and improve treatment options for patients with AL amyloidosis, it is 
critical to achieve a better understanding of the disease, especially the fibrillogenesis 
process, to help early intervention. Several factors 
(54-61)
 may contribute to the 
pathogenesis of AL amyloidosis, e.g. variations in primary sequences, post-translational 
modifications (PTMs) and LC association with other molecules.  
Initially, researchers focused on the primary sequences of amyloidogenic LCs, 
trying to determine single amino acid substitutions which might be crucial for fibril 
formation 
(54, 62-64)
. However, as discussed in previously, LC sequences have great 
variability, especially in the CDRs of the V region, making it hard to draw a decisive 
conclusion. Stevens et al. proposed a three-step process for LC amyloid fibril formation: 
dimer formation; dimer-dimer interaction and fibril formation 
(65)
. Some amino acid 
positions in the VL regions of both λ and κ LCs are believed to be more amyloid-
associated; these are mostly located in surface or solvent-exposed areas of the LC and are 




hydrophobicity and charge, amino acid residues at such key positions may favor 
dimer/dimer-dimer formation or interactions with other accessory molecules. In contrast, 
Hurle et al. proposed that the amino acid substitutions could interfere with the protein 
folding process, resulting in unfolded structures 
(62)
. Protein folding is an intricate process 
involving balance between conformations of different energy states 
(66)
. A polypeptide 
chain can adopt multiple intermediate conformations before it reaches the one most stable 
for the native protein 
(66, 67)
. Incorrectly folded protein intermediates, including β-sheet 
structured aggregates, usually can be converted to the native, low energy state by 
refolding or are degraded if proper folding attempts fail. When both approaches are 
unsuccessful, amyloid fibrils may form 
(57, 68, 69)
. It is interesting to note that λ LCs are 
more frequently associated with AL while κ LCs have a higher tendency to contribute to 
other non-amyloidogenic LC diseases 
(70)
. Although these two types of LCs do not differ 
in their functions, λ LCs are found in dimeric form while κ LCs can exist as dimers and 
monomers. LC dimers are more difficult for the kidney to filter and this may contribute to 
the higher frequency of λ amyloidogenic LCs, i.e. 2/3 of patients have λ LC-associated 
AL amyloidosis 
(71)
. Moreover, it has been suggested that certain κ and λ LCs, which are 
further classified by subgroup based on VL sequence 
(72-74)
, may have a higher tendency 
to form amyloid fibrils. For example, LC proteins of the λ6 subfamily are thought to be 
exclusively expressed in patients with AL amyloidosis 
(75-78)
.  
Post-translational modifications (PTMs) may also play a key role in LC fibril 
formation as they can alter the surface or structural properties of proteins. Connors et al. 




disulfide-linked dimerization, S-cysteinylation, S-sulfonation, 3-chlorotyrosine formation, 
N-glycosylation and fragmentation 
(60)
. The exact role of these PTMs in LC 
fibrillogenesis is unknown and should be elucidated for a better understanding of the 
pathologic process. It is already known that S-sulfonation and S-cysteinylation at 
cysteine-10 of transthyretin (TTR) can affect the stability of the native TTR tetramer and 
thus, impact the formation of amyloid fibrils 
(79-81)
. Stevens studied a database of 
approximately 370 κ and λ LCs, and found 18% (22/121) of κ1 LCs were N-glycosylated; 
18 of the 22 were amyloidogenic 
(55)
. The N-glycosylation sites most likely resulted from 
somatic mutations, since these sites were not encoded in the κ1 germline genes. However, 
no significant correlation of N-glycosylation with amyloidogenecity was found in the 
database study set of λ LC proteins. The role of N-glycosylation in fibrillogenesis is still 
undetermined 
(58, 82, 83)
. However, it is possible that LC glycosylation may influence the 




Fragmentation or truncation of LC proteins in the amyloid deposits is frequently 
observed; the fibrils are usually composed of N-terminal fragments containing an intact 
VL region and a short stretch of the CL domain 
(85)
. It has been suggested that removal of 
the CL domain promotes LC fibril formation 
(65, 86)
. In vitro experiments have shown that 
Bence Jones proteins isolated from urine of patients with (or even without) AL 
amyloidosis can yield VL region fragments that are amyloidogenic upon treatment with 
enzymes 
(87-89)
. Conversely, there are reports demonstrating the presence of full-length 






amyloid fibrils can be generated using full-length LC purified from patient urine 
(86, 92)
. 
Recent research reported by Klimtchuk et al. indicates that the CL region may influence 
the thermal stability of the protein and thus, play an important role in the fibrillogenesis 
process 
(93)
. Although rare, LC fibrils mainly composed of the CL domain have also been 
observed 
(63, 91, 94)
. The contribution of in vivo proteolysis in the pathologic mechanism of 
amyloid fibril formation has not been established. It is not known if the generation of LC 
fragments initiates or accelerates fibrillogenesis, or whether the presence of full-length 
LC is sufficient. Also unclear is whether or not LC proteolysis occurs before or after 
amyloid deposition; the LC fragments could be produced at the first step of fibril 
formation or may arise as products of degradative modifications 
(54, 95, 96)
.  
Finally, other types of molecules are found co-deposited with the LC in AL 
amyloid fibrils. While experiments have shown that amyloidogenic LCs or fragments 
alone can form fibrils in vitro 
(92, 97-101)
, co-deposited or accessory molecules may assist in 
the in vivo process. Conversely, the presence of these components may be supplementary 
or they participate in other aspects of the disease. Serum amyloid P component (SAP) is a 
protein found in almost all types of amyloid deposits. It is a homopolymer of 10 subunits, 
formed into two noncovalently bound pentamers 
(102)
. In the presence of Ca
2+
, SAP itself 
spontaneously aggregates 
(103)
. It is now thought that SAP binds amyloid protein 
aggregates and prevents proteolytic cleavage, inhibiting the removal of fibrils via the 
normal protein degradation machinery 
(104)
. Apolipoprotein E preferentially co-localizes 
with amyloid fibrils, indicating that it may play a potential role as “a pathologic 




also found in amyloid extracts include actin, clusterin, and keratin 
(48)
. 
Glycosaminoglycans (GAGs) such as heparan sulfate proteoglycan and dermatan sulfate 
(106-108)
 are also frequently observed. GAGs, which are long unbranched 
heteropolysaccharides with a disaccharide as the repeating unit, tend to interact with 
varieties of amyloid proteins, including amyloidogenic LCs 
(109)
. It is not clear about the 
consequences from association of AL and GAGs. However, more and more evidences 
show up to support the positive role of GAGs in formation of immunoglobulin LC 





LC protein analysis 
 In standard diagnostic testing, the presence of amyloid is usually first confirmed 
by Congo red (CR) staining of a tissue biopsy, which will show an apple-green 
birefringence under polarized light upon binding of the dye to the fibrils. Further typing 
of the amyloid protein relies on immunohistochemical and more recently mass 
spectrometry methods. Immunohistochemical testing requires the use of proper 
antibodies (anti-sera) and controls, which are not always readily available and yield 
results oftentimes that are difficult to interpret; this latter situation can lead to 
misdiagnosis 
(113-117)
. Immunohistochemistry approaches have been widely used to detect 
LC fragments in tissue deposits 
(118-121)
. Enqvist et al. studied κ-type LC deposits in 
multiple organs from different patients using three separate antibodies which recognized 




terminal regions of the κ CL domain, respectively 
(118)
. No accurate LC sequence for each 
deposit was available with this method. When the CL region of the LC has been lost or 
severely truncated, the epitopes pertinent to the commonly used antibodies may be 
missing or incomplete; immunochemical approaches in these cases cannot detect the 
residual, primarily VL region of the LC present in the amyloid deposit. 
 Usually patient-specific amyloidogenic LC gene sequences are derived from the 
plasma cells found in bone marrow aspirated samples 
(122)
. Total RNA is extracted to 
synthesize cDNA, which is then amplified by PCR using the proper primers and DNA 
sequencing. This amplification and sequencing cycle is repeated several times to correct 
minor nucleotide errors. The LC protein sequence is deduced from the cDNA sequence 
information. The whole procedure is very time consuming and expensive. More 
importantly, amino acid sequences deduced this way may contain inaccuracies resulting 
from variations introduced during the transcription and/or translation processes. 
Furthermore, PTMs such as glycosylation and truncation are not identified with this 
method. Another disadvantage is that bone marrow samples are not always available or 
optimal for this analysis. In some cases, protein sequencing is carried out with Edman 
degradation for analysis of proteins extracted from urine or tissue samples. This method, 
however, requires the presence of an unblocked or unmodified N-terminus 
(123-125)
, not the 
case with many amyloidogenic LC proteins. Mass spectral analysis, as discussed in detail 
below, can address and usually overcome each of these complications. 
 Several types of clinical samples are normally used in studies of AL. A 




pathologic factors. Serum samples are used for analysis of circulating free LCs. Ratios of 
κ and λ LCs or the absolute serum concentrations of LCs are currently used for 
prognostic evaluation of AL 
(126, 127)
. Secreted LCs extracted from the urine, have been 
extensively studied since they are usually available in large amounts and can easily be 
purified 
(128)
. LCs can be purified from urine with size-exclusion chromatography (SEC) 
after small molecules and albumin are removed. Biopsy and autopsy specimens are also 
useful tissue sources. Biopsy material, usually limited in amount, is routinely formalin-
fixed and paraffin-embedded (FFPE) for histologic analyses. Autopsy samples can be 
available in both fresh frozen (unfixed) and fixed forms. Methods for protein extraction 
from fresh frozen tissues have long been employed for amyloid fibril protein analysis 
(129, 
130)
. FFPE tissue blocks are easily stored and more readily available, especially for 
samples collected in past years. Recently, more attention has been paid to this type of 
sample. Murphy et al. successfully extracted amyloid proteins from 4-μm thick FFPE 
sections of Congo red positive human tissues (multiple types) using guanidine and 
successfully identified the amyloid proteins 
(131)
. Vrana et al. used laser microdissection 
to directly capture Congo red stained tissue from FFPE sections and mass spectral 




 Mass spectrometry (MS) instruments are now widely used for biomolecule 
characterization 
(133-136)
. The capability of performing de novo sequencing and PTM 




proteins and AL amyloidosis. The recent development of new MS instruments should 
facilitate new research approaches enable us to expand our knowledge of this disease. 
 
1.2 Mass Spectrometry 
A mass spectrometer is a tool for analyzing molecules accomplished by 
generating spectra that may be presented in the format of signal abundances vs. mass-to-
charge ratio (m/z) information. The instrument is composed of three parts: 1) an ion 
source, which converts the (usually neutral) analytes to gas-phase ions; 2) a mass 
analyzer, which separates ions based on their m/z values; and 3) a detector, the electronic 
device which records ion currents as a function of m/z during scans of the mass analyzer. 
Samples can be introduced in different forms through solid, liquid, or gas phases. Some 
analyzers enable the instruments to perform so called tandem MS analysis, where 
precursor ions of interest generated in the first stage of MS analysis are selected and 
fragmented to give structural information. A variety of fragmentation/activation methods, 
each having different characteristics, may be available and may be utilized in 
combination with different types of mass analyzers. The review here will focus on the 
MS configurations for organic biomolecules (especially peptides, proteins, and glycans) 
analysis. A complementary method, inductively coupled plasma (ICP)-MS, enables 
quantitative elemental analysis of metals and some non-metal elements; this can be 
accomplished on elements in their pure forms, as well as when they are components of 









 Many ion source designs have been used to ionize a neutral molecule. Over the 
years, ionization has been achieved by striking the analytes with agents such as electrons, 
photons, other ions or accelerated neutral molecules.  
 Electron ionization (EI) 
(140)
 is widely adopted for analysis of volatile samples, 
making it a perfect companion to gas chromatography (GC)/MS. Samples entering the 
ion source encounter abeam of ~70-eV electrons, leading to the production of molecular 
ions and abundant fragments, from which structural information can be derived. 
However, for some samples, even at reduced voltages, EI may impart so much energy 
that no molecular ions survive and thus, the encounter is too “hard” to give molecular 
weight information. EI is good for small non-thermolabile organic molecules.  
 Chemical ionization (CI) is a method complementary to EI. It is “softer” and can 
be used for the cases when no molecular ions are left intact in the EI mass spectrum. In 
CI, a reagent gas with a low ionization potential is first ionized by EI and the resulting 
gaseous ions then interact with and ionize the neutral analyte molecules 
(141, 142)
. 
Commonly used reagent gases include methane, ammonia and isobutane. Negative 
chemical ionization (nCI) is possible with reagent gases capable of forming negative 
ions, such as species containing halogen atoms 
(143)
. Like EI, CI requires the sample to be 
introduced as a gas, so it is not compatible with thermally unstable compounds. A 
variation of CI, called atmospheric pressure chemical ionization (APCI), can be coupled 




with a corona discharge, in which H3O
+
 is produced for transferring protons to analyte 
molecules. Negative APCI is also possible with specific analytes. APCI under special 
operating conditions can be used for peptide analysis 
(144)
. 
 Fast atom bombardment (FAB), introduced by Barber et al. in 1981 
(145)
, is an 
even “softer” ionization approach. A mixture of sample and matrix is bombarded with 
high velocity neutral molecules, including inert gases like argon and xenon, under 
vacuum conditions. The matrix is a substance with low volatility, glycerol and 
thioglycerol for instance, which can create a protective environment by absorbing most of 
the energy, forming neutral and charged clusters and transferring a charge to the sample, 
which gets protonated or deprotonated. FAB MS is used to analyze non-volatile or 
thermolabile samples, including peptides 
(146)
. As a result, there was a boom in peptide 
studies with MS in the 1980s. In addition to the relatively stable molecular ions, it was 
noticed that ionization of peptides with FAB could also produce predictable fragment 
ions 
(147)
 and that the stability of the ion beam made selection and controlled dissociation 
of molecular species quite feasible. FAB-MS was widely applied to deduce peptide 
sequences 
(148)
 and PTMs. It was used for sequence verification, determination of variants 
assignment of disulfide-bonds, and other analyses 
(149-153)
. With FAB-MS, Carr et al. 
analyzed tryptic peptides derived from bovine ribonuclease B (a glycoprotein) with or 
without additional treatment of the sample with N-glycosidase F (also known as PNGase 
F) to release the glycan 
(154)
. By comparing the spectra to check on the 
disappearance/appearance of some peaks, the glycosylation sites and compositions of the 








 Developments of matrix-assisted laser desorption/ionization (MALDI) 
(157-159)
 and 
electrospray ionization (ESI) 
(160)
 in the late 1980s led to further, more dramatic advances 
in the application of MS to biomolecule analysis. Both techniques are soft enough to 
minimize sample fragmentation during the ionization process. For MALDI, samples are 
co-crystallized with matrix molecules on a metal plate, sometimes with doping of cations 
or anions, and ionized by irradiation with a laser whose wavelength falls within the 
absorption bandwidth of the matrix. The exact mechanism of MALDI is not established 
although several models have been proposed 
(161-163)
. The matrix molecules apparently 
play an important role in the ionization process. Upon laser irradiation, they become 
excited and are ejected into the vacuum, carrying the analytes and cations/anions along 
with them. The matrix molecules are then evaporated and the analytes get ionized by 
proton or ion transfer. Because the matrix absorbs most of the energy and no efficient 
energy transfer happens between the matrix and the analytes, MALDI is a rather soft 
ionization strategy 
(162-165)
. Commonly used lasers include ultraviolet (UV) lasers such as 
the 337 nm nitrogen and 355 nm frequency-tripled Nd:YAG lasers, and the infrared (IR) 
2.94 μm Er:YAG laser. Different matrices are available for a variety of analytes and the 
analysis of choice 
(166-168)
. For UV MALDI, 2,5-dihydroxybenzoic acid (DHB) is the 
most versatile matrix; it can be employed for peptides, glycoproteins, glycolipids, 
carbohydrates and nucleic acids. While α-cyano-4-hydroxycinnamic acid (CHCA) can be 




molecular weights up to 30 kDa. Reducing matrices including DHB, 2-aminobenzamide 
(2-AA) and 1,5-diaminonaphthalene (DAN) can be used to achieve in-source decay (ISD) 
fragmentation 
(169)
. Normally, singly charged ions are obtained with UV-MALDI. IR-
MALDI expands the matrix collection and is a milder ionization method with 
diminishing fragmentation. The generation of multiply charged ions is more likely with 
IR-MALDI and thus, it can be useful for ionization and detection of molecules with high 
molecular weights. In addition, the use of IR lasers results in a deeper sampling depth. 
Eckerskorn et al. separated human blood plasma with two dimensional (2D) sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and electroblotted the 
proteins onto a PVDF membrane, which was then incubated in succinic acid (0.3 mol/L), 
the matrix solution 
(170)
. Direct scanning of the membrane with IR-MALDI-MS showed a 
protein localization pattern consistent with that obtained by silver staining of the gel. 
Guittard et al. directly sampled and differentiated glycosphingolipids from thin-layer 
chromatography (TLC) plates and transfer membranes with IR-MALDI-MS 
(171)
. In both 
cases, samples of limited amounts can be analyzed without laborious down-stream 
treatments. 
 ESI ionizes samples in a flowing liquid 
(160, 172)
. It can easily be coupled with 
HPLC for on-line sample analysis. An analyte-containing, usually organic, solution is 
sprayed from a fine needle (emitter) at high potential (2-6 kV). The charged droplets then 
fly to the vacuum interface down the potential gradient, during which the solvents 
evaporate, leading to unstable droplets of smaller sizes with higher surface charge 




create smaller and more stable droplets, a process called Coulomb fission. The 
desolvation and Coulomb fission occur repeatedly. Two major theories are proposed for 
the mechanism of the final ionization step. One hypothesis proposes that repeat 
desolvation and Coulomb fission lead to formation of single ions 
(173)
, while the other 
theory suggests that single ions are released from surfaces due to Columbic repulsion 
(174, 
175)
. An inert sheath gas or heating of the emitter is usually applied to help the solvent 
evaporation process. A typical spray solution can be acetonitrile (ACN): water: formic 
acid (FA), 50: 50: 0.1 (v:v:v) or methanol (MeOH): water: FA, 50: 50: 0.1 (v:v:v) with 
adjustable concentrations of organic solvents and acids to achieve a better solubility. 
Compared with UV-MALDI, ESI tends to form multiply charged ions (no excess of 
fragmentation either), which facilitates the analysis of macromolecules, such as Ig 
proteins. Since a matrix is not used in ESI, ions with matrix adducts are not produced, 
although low abundance peaks that correspond to water, organic solvent or buffer adducts 
may be observed. A disadvantage of ESI is the lower tolerance of this method for salts 
and contaminants, and thus, requiring more sample cleanup. The phenomenon called 
ionization suppression can happen when analyzing a sample mixture. In the 1990s, a 
technique called nanoESI was introduced 
(176, 177)
. It uses a smaller spraying orifice (1-2 
μm) and the sample volume can be downsized to 0.2 μL. The authors reported that 
femtomole amounts of proteins separated on a PAGE gel were successfully sequenced 
with nanoESI-MS. Today, most laboratories that perform high sensitivity LC/MS 








 A mass analyzer is another key element of a mass spectrometer. It uses electric 
and/or magnetic field(s) to separate ions based on their m/z values. Some mass analyzers 
also have the capability to select ions of interest and/or perform ion activation for 
multistage (tandem) analysis. Mass analyzers may have different performances in terms 
of resolving power, mass accuracy, mass sensitivity, dynamic range, and scan rate. A 
mass spectrometer may be equipped with a single type or several types of mass 
analyzer(s) to achieve proper functioning.  
 Time-of-flight (TOF) is a mass analyzer with the simplest mechanism where the 
m/z is deduced from the flight time of the ions 
(178-180)
. Ions are accelerated in an electric 
field and then travel through a fixed-length- field-free drift tube (in the vacuum). If no 
initial velocity is considered, the electric potential of an ion is converted to kinetic 
energy; velocity and drift time for each ion in the drift tube can be derived from the 











                                           (1.2) 
U, m, z, v, t and L are strength of the electric field, mass of the ion, charge of the ion, 




 When L is fixed, the drift time will be proportional to the square root of m/z if U 
is held constant. If the drift time is recorded, m/z can be calculated. The model above is 
quite simplified on several levels. In fact, different ions are accelerated at different 
velocities and the faster ions will spend less time in the drift tube, adding to the total 
travel time. Moreover, initial velocity due to ionization is not negligible. To improve the 
resolving power, a reflectron replaces the linear drift tube or a technique called delayed 
extraction is adopted. In the former case, ions are reflected by an electric field gradient 
with slower ions penetrating less deep to compensate for the extra time spent outside the 
reflectron 
(181)
. In the delayed extraction, usually used when MALDI is the ionization 
method, acceleration of the target ions into the drift tube does not immediately follow the 
laser irradiation 
(182)
. Instead, a selected voltage is applied a short time after the ionization 
pulse, so that the slower ions experience a stronger electric field and are accelerated 
sufficiently to catch up with the others. 
 TOF analyzers are usually used in conjunction with the pulsed MALDI source. 
However, coupling with a continuous ESI source is possible when orthogonal injection of 
the ions is applied. Simple TOF analyzers are mostly used for molecular weight analysis, 
although peptide sequence information or other structural details may be elucidated based 
on recording of the post-source decay (PSD) spectrum with a reflectron TOF 
(183-185)
. 
However, the advent of two-stage TOF/TOF analyzers and other types of tandem MS 
analyzers, that include more than one TOF separation, have diminished the necessity for 




 A quadrupole mass analyzer is a small and inexpensive swept beam instrument 
with low resolution. It is made of a set of four parallel cylindrical rods 
(186)
. Opposing 
rods are electrically connected and a radio frequency (rf or AC) is applied to the two pairs 
of rods with a superimposed direct current (DC) voltage. The ion movement inside can be 
described with the Mathieu Differential Equation 
(187)
. Under given AC and DC 
conditions, only ions of a certain m/z range are sufficiently stable to pass through the 
rods. The analyzer can act as a mass filter, collision chamber, or scanning device. 
Commonly used in the form of a triple quadrupole (capable of tandem MS analysis, 
tandem in space setting), these instruments can also constitute the first stage of a hybrid 
with another mass analyzer, such as a TOF. 
In addition to the two types of mass analyzers mentioned above, there is a large 
family of the ion trap mass analyzers. The 3D quadrupole ion trap (QIT) is a Nobel Prize 
winning invention by Wolfgang Paul. It is closely related to a quadrupole mass analyzer 
(187-189)
. Instead of four hyperbolic rods, the 3D trap has a set of opposing hyperbolic end 
cap electrodes, as well as a hyperbolic end ring electrode. Ions are trapped inside the 
analyzer with application of AC and DC. The ion stability can also be explained by a 
Mathieu Equation. Through adjustment of the operating parameters, a QIT can be made 
to work in different modes. It can either directly scan the m/z range, or perform ion 
activation for tandem MS analysis (tandem in time setting, MS
n
, n ≥ 2). A linear ion trap 
(LIT or LTQ) or the 2D QIT is an improvement of a 3D QIT with different electrode 






analyzers, especially an LTQ with high sensitivity and fast scan rate, can be used alone or 
coupled with other analyzers.         
 Currently, a Fourier transform ion cyclotron resonance (FT-ICR) mass analyzer 
offers the best mass accuracy and highest mass resolution. Since its introduction by 
Comisarow and Marshall in 1974, this instrument has been installed widely 
(192)
. 
Intrinsically, it is an ion trap instrument that contains ions in an ICR cell, which has 
electric fields applied and placed in a fixed magnetic field. Different ICR cells have been 
developed; the simplest one has a configuration of three pairs of orthogonal metal plates 
or cubic cell. Ions exhibit cyclotron motion inside the cell. The m/z of an ion can be 




                                           (1.3) 




                                             (1.4) 
where B is the strength of the magnetic field. The frequencies are only related to the 
magnet strength and the m/z value. 
 A constant cyclotron motion is of limited value on its own. Through ion 
excitation, three different purposes can be achieved: detection, activation and ejection. 
Ion excitation can be accomplished by several means. An azimuthal electric field may be 
added under which condition only ions of single-frequency can be excited 
(193, 194)
. 
Otherwise, broadband excitation methods are used, including the most versatile stored 






With high mass accuracy and resolving power (≥ 50,000 at m/z 400 with a 
broadband mode or ≥ 1,000,000 with a narrowband mode), an FT-ICR analyzer can 
differentiate ions with close m/z values. This instrument is now extensively utilized in 
applications involving proteomics studies 
(196-200)
. The resolving power of the analyzer is 








                               (1.5) 
The full width of a peak at half-maximum peak height for the mass and the angular 
frequency are represented by ∆𝑚50%  and ∆𝜔50% , respectively. Currently, a 
superconducting magnet of 15 Tesla (T) is commercially available while a specially 
constructed 21-T magnet has recently been installed in Prof. Marshall’s laboratory (201). 
However, the cost escalates with increasing field strength. 
The orbitrap is a less expensive and physically much smaller substitute for the 
FT-ICR; this instrument was optimized and incorporated into a commercial tandem MS 
system by Makarov in the late 1990s 
(202)
. It has a configuration of an inner spindle-like 
electrode with a coaxial outer barrel-like electrode, forming a quadro-logarithmic 
potential distribution of electrostatic field with a DC applied between the two electrodes 
(202, 203)
. No magnet is involved in the operation of the orbitrap which is a modification of 
the Kingdon trap developed in the early 1920s. The ions are orbitally trapped as they 
orbit and oscillate around the central electrode in the orbitrap. The m/z is derived from the 








where k is a parameter determined by the geometry of the orbitrap and the applied 
potential 
(203, 204)
. Similarly, we can see that the axial frequency is proportional to the 
inverse square root of the m/z and is independent of the initial states of the ions, including 
the spatial and velocity distribution. The orbitrap offers a great advantage over the 
Kingdon trap with higher mass accuracy and resolving power. Different hybrid models of 
the orbitrap have been marketed by Thermo Scientific
TM
 and are widely used for protein 





 Tandem MS (MS
n
, n≥ 2) analysis is used to deduce protein and peptide 
sequence/structure information. For the product ion scan technique used throughout this 
dissertation, ions of interest (parent/precursor ions) are selected, fragmented, and 
followed by detection of the product (fragment) ions. In the case of triple quadrupole, Q-
TOF and TOF-TOF analyzers, ion selection, fragmentation, and product ion scans are 
done in different places. This is called tandem-in-space analysis. In the case of tandem-
in-time analysis, such as with ion trap analyzers, these three steps can be accomplished in 
the same ion trap with manipulation of the electric field.  
 Depending on factors like the primary sequence, charge state, fragmentation 
method, and excitation energy, different types of product ions can be produced from 
peptide/protein fragmentation. The nomenclature for the major fragment ions is shown in 
Figure 1.2 
(209, 210)
. The mass difference between two consecutive ions of the same type 




cleavage ions may be produced due to double backbone cleavages. An important type of 
internal fragment is called an immonium ion, with a single side chain due to both a-type 
and y-type cleavages around the same amino acid residue. Some amino acid residues may 
produce immonium ions having relatively high signal intensities, and these can be used as 
an indicator for the presence of the residue 
(211)
.   
 
    




 Collision-induced dissociation (CID) also known as collisionally activated 
dissociation (CAD) is one of the most commonly used activation methods 
(212-214)
. 
Accelerated parent ions are fragmented by colliding with gas molecules, usually nitrogen, 
argon or helium. The collision cell can be integrated with various types of mass analyzer 
systems including hybrid instruments with quadrupole and ion trap analyzers. Activation 
energy is introduced as the kinetic energy of the parent ions. Low energy CID (up to 200 
eV) is frequently used for peptide sequencing and PTM analysis, and yields primarily b- 
and y-types of fragment ions from backbone cleavage at the amide bonds. Increasing the 





partial or full elimination(s) of the amino acid side chain(s). The immonium ions in the 
low-mass region of the MS/MS spectrum may provide additional information on the 
amino acid composition 
(211)
 and/or some post-translational modifications.  
 One major drawback with peptide sequencing using CID is that fragmentation 
strongly depends on primary sequence and the sites favored for charge localization 
(215, 
216)
. For example, enhanced fragmentation may be observed at the C-terminal side of 
histidine, aspartic acid, and glutamic acid while cleavages of the glycine-glycine and 
glycine-alanine peptide bonds have low efficiency most of the time. All these can lead to 
incomplete peptide bond cleavage and limited sequence coverage. In addition, some 
labile PTMs, such as phosphorylation, can undergo neutral losses. 
A family of electron-related fragmentation (ExD) methods was developed in the 
late 1990s and includes electron capture dissociation (ECD) and electron transfer 
dissociation (ETD) 
(217, 218)
. For ECD, low energy (~ 1 eV kinetic energy) electrons are 
captured by a multiply charged parent ion. Electric potential energy released from this 
combination process is utilized for parent ion fragmentation. For ETD, a radical anion 
produced in an NCI source is used. Anthracene and fluoranthene are among the reagents 
commonly used to provide the anion 
(219)
. Both methods produce c- and z-types of ions, 
although b- and y-types of ions can be observed as well, probably due to the occurrence 
of some CID at the higher pressure in the ETD cell 
(220)
. Because of side-chain cleavages, 
aspartyl and isoaspartyl in peptides, produced from either deamidation of asparagine or 
isomerization of aspartic acid, can be differentiated with both ECD and ETD 
fragmentation with formation of specific c ion or z ions 
(221-223)




isoleucine residues can also be differentiated with ECD by specific w ions 
(224)
. In both 
ECD and ETD spectra, most of the fragment ions result from backbone bond cleavages 
while labile PTMs can be retained 
(206, 225, 226)
. ECD and ETD are also used for studies of 
oligonucleotides and oligosaccharides 
(227, 228)
.  
ECD fragmentation has been performed mainly with an FT-ICR instrument since 
low energy electrons and long interaction times are required and these prerequisites can 
only be fulfilled by ion trapping in an electromagnetic field. The possibility for carrying 
out ECD fragmentation in a less expensive rf ion trap instrument has been demonstrated 
by Baba et al. 
(229)
. They designed an rf-ECD cell with no rf component, but with a 50 
mT magnetic field axially. ETD using anions, has no such discrimination against ion trap 
or Q-TOF based instruments. Prof. Barofsky designed a five-magnet electromagnetostatic 
cell and later improved it as a two-magnet cell which has the capability of performing 




Approaches of MS-based proteomics analysis 
 Sequence/PTM identification and quantitation of proteins can be achieved with 
different approaches in MS-based proteomics studies (Table 1.3) 
(206)
. In bottom-up 
analysis, proteases are employed to cleave proteins into peptides prior to MS analysis. 
This technique is widely used for complex samples and is compatible with gel-based 
protein separation methods. Because peptides are to be analyzed, a great selection of 
instruments can be applied. Data processing can be convenient, with the availability of 






. However, it is difficult to get molecular weight information 
with this approach due to the possibility for incomplete sequence coverage, especially in 
the loss of terminal peptides. In addition, the sample handling process may cause loss of 
PTMs and bias peptide representations. For PTM sites that have incomplete occupancy, 
the interrelationship of two or more PTMs on a single protein molecule cannot be 
determined via bottom-up analysis.  
 Intact proteins may be analyzed directly using top-down analysis. Proteins are 
fragmented in the MS instrument after sample introduction. CID fragmentation can be 
used, but ECD and ETD are generally more informative since these latter methods 
produce mostly backbone cleavages which generally yield better sequence coverage and 
conserve the PTMs. Recently, Mao et al. reported top-down analysis of a therapeutic 
IgG1 (about 148 kDa) with ECD fragmentation on a home-built 9.4 T FT-ICR mass 
spectrometer 
(200)
. Sequence coverages of 32% and 35% were obtained for the LC and 
HC, respectively. The major drawback of top-down analysis is that extensive sample 
purification may be needed. Instruments with high resolution and high mass accuracy are 
usually necessary. 
An intermediate middle-down approach has been used by some investigators, 
including Prof. Kelleher 
(235)
. Instead of analyzing mixtures mainly of small peptides (< 2 
kDa) or large intact proteins, the middle-down method focuses on analyzing peptides 
with molecular weights ranged from 2-20 kDa generated with carefully selected enzymes 









Table 1.3 Approaches in mass spectrometry proteomics.
a










Four MS instruments have been utilized for the research reported in this 
dissertation (Table 1.4), especially the latter two which are extensively applied. Typical 
tandem MS methods are listed. Additional methods are also available, such as infrared 
multiphoton dissociation (IRMPD), in which parent ions absorb multiple infrared photons 
and get fragmented upon infrared laser excitation 
(237)
. Laser-induced dissociation (LID), 
reflectron in-source decay (reISD) and higher-energy collisional dissociation (HCD) will 
be discussed in the following sections. 
 
Table 1.4 Instruments used in this dissertation. 
Instrument Ion Source Mass Analyzer Tandem MS Capability 
amaZon™ speed ETD ESI LIT (LTQ) CID, ETD 




MALDI TOF-TOF CID, LID, reISD 
LTQ-Orbitrap XL™ ESI LTQ-Orbitrap CID, HCD, ETD 
 
1.2.2 MALDI-TOF/TOF Mass Spectrometer 
This instrument is capable of performing several types of tandem MS analyses in 
addition to the MS scan for peptide mass fingerprinting (PMF) (Figure 1.3) 
(238)
. It takes 
advantage of a MALDI source, which has high sensitivity and high tolerance for salts and 
contaminants. As mentioned earlier, a reflectron analyzer can be operated in the PSD 




fragmentation efficiency, and the spectra have low mass resolution. The ultrafleXtreme, 
with a collision cell, a Lift cell and a TOF-TOF mass analyzer, can perform true MS/MS 
with fragment ions generated via CID or LID and also a “pseudo-MS/MS” called reISD. 
The CID is a high-energy type analyzer and thus, is possible to differentiate isomeric 
residues such as leucine and isoleucine because they produce different side-chain 
fragment ions. Since ion fragmentation occurs after parent ion acceleration, each parent 
ion will generate a group of fragment ions having the same velocity. In the CID 
experiment, by adjusting the voltage at the timed ion selector (TIS), the parent ion of 
interest and its fragment ions can be selected and detected. For LID, the parent ion is also 
selected by TIS while ion fragmentation is performed with a Lift cell by adding an 
electric field. In contrast, the in-source decay (ISD) happens promptly due to excess 
energy transfer during the ionization process and is complete before the ions are 






Figure 1.3 Schematic diagram of the MALDI-TOF/TOF mass spectrometer. 




 Recently, in situ MALDI-imaging MS (IMS) analysis of both small and large 
biomolecules, including lipids and amyloid proteins, is a new field which has emerged 
(239-242)
. Marsching et al. compared renal localization of different sulfatides in mice with 
sulfatide storing arylsulfatase A-deficiency and controls, and showed a difference in 
expression and metabolism of these molecules in the diseased condition 
(243)
. Direct 
MALDI-IMS of small proteins is also possible, whereas for proteins > 20 kDa, a 
procedure called on-tissue digestion is usually performed beforehand. Nakanishi et al. 
applied this technique to FFPE tissue slides from patients with amyloidosis 
(244)
. MALDI-
MS/MS scans of the on-tissue tryptic digested slides identified amyloidogenic proteins 
from CR-positive regions, indicating the possibility of using this method as a 






1.2.3 UPLC ESI Orbitrap Mass Spectrometer 
An LTQ-Orbitrap XL (Thermo Fisher Scientific) (Figure 1.4) upgraded with an 
ETD function (ETD ion source installed at the rear of the instrument, not shown in the 
figure) has been used extensively for the research reported in this dissertation 
(203, 205, 245)
. 
It is a hybrid instrument with LTQ and orbitrap analyzers. All commercial orbitrap 
instruments are now equipped with a curved linear trap called a C-trap, which is usually 
used for ion storage before injection into the orbitrap analyzer. For the system set-up in 
our laboratory, the sample solutions are introduced through several interfaces, including 
direct infusion with a syringe, nanoESI delivery with a TriVersa NanoMate
®
 (Advion), or 
on-line sample injection with an ultra-performance liquid chromatography (UPLC) 
system.  
 
Figure 1.4 Schematic diagram of the LTQ-Orbitrap XL mass spectrometer. 








For tandem MS analysis, fragment ions generated by CID or ETD in the LTQ can 
be detected either in the low-resolution LTQ or in the high-resolution orbitrap.  In 
addition, higher energy dissociation (HCD) fragmentation can be performed either in the 
C-trap or in the additional octopole collision cell 
(245)
. HCD can produce triple 
quadrupole-like fragmentations while still able to record ions in the low m/z region. Due 
to the characteristics of ion motion in an ion trap, a higher rf voltage can lead to higher 
fragmentation energy and thus, better excitation; however, this can also raise the low 
mass cut-off, i.e. the m/z value below which fragment ions are unstable and ejected. As 
an estimate, the “one third rule” is commonly adopted, wherein the lowest m/z of the 
trapped ions should exceed 1/3 of the precursor ion. For HCD, especially the second 
fragmentation configuration which is available with LTQ-Orbitrap XL, precursor ions 
can be fragmented in the additional collisional cell (filled with collision gas like 
nitrogen), sent back to the C-trap, and injected to the orbitrap analyzer. The mass cut-off 
problem associated with the increased rf voltage is thereby circumvented and all the 
peaks are measured with high resolution and mass accuracy. Combination of these 
features makes HCD a good tool for de novo sequencing 
(245, 246)
. 
This instrument is now widely used for protein/peptide studies. Besides de novo 
sequencing, HCD is also good for protein identification, quantification, and PTM 
analysis. With newer models introduced to the orbitrap family, an orbitrap instrument is 








1.3 Dissertation Overview 
This dissertation focuses on the sequence determination and PTM analysis of 
amyloidogenic human Ig LC proteins of λ type (Chapters 2-4) and a tobacco plant-
derived therapeutic Ig protein (Chapter 5) by MS-based methods. The work present is 
aimed to explore two hypotheses: (1) Amyloidogenic Ig LCs are heavily modified, which 
may be different considering the sources of the proteins, especially the proteolytic 
process. Some of these modifications may be used as biomarkers for the AL amyloidosis 
or associated conditions. (2) Some weak points in the HC sequence may be responsible 
for the recurring of degraded products of mAb produced in plants. 
In Chapter 2, de novo sequencing results for LC proteins extracted from a fat 
biopsy are presented. Chapter 3 details comparative studies of PTMs, especially 
fragmentation patterns, identified in λ6 LCs from kidney, serum and urine samples of 
five patients. In Chapter 4, PTM characterization of a λ2 LC recovered from a urine 
sample analyzed using a combination of instrumental and chemical approaches is 
reported. Studies of the mAb extracts are presented in Chapter 5 which includes the 
extensive investigation using top-down MS, HPLC separation, and bottom-up MS 
analyses. The sequence of both the HC and the LC, several truncated forms, and also 
other PTMs were identified. 
In this work, MS instruments have shown their great advantages in analyzing Ig 
proteins from different sources and their capabilities for performing PTM analysis along 
with sequence verification. Mass analyzers are powerful tools for expanding our 




forms. The approaches described herein have great importance for the pharmaceutical 







De novo Sequencing and Characterization of Immunoglobulin Light Chain Proteins 
Deposited in Human Abdominal Fat Aspirate and Serum 
 
2.1 Introduction 
As more than 20 wild-type or variant proteins have been identified in systemic 
amyloidosis 
(48)
, an accurate typing of the amyloidogenic protein involved is the critical 
next step in initiating a proper therapeutic plan, once the presence of amyloid fibrils has 
been confirmed with positive CR staining. Classical typing methods rely heavily on 
immunohistochemical approaches, which have quite some chance of misdiagnosis 
(113-
117)
. These methods require application of proper antibodies and controls, not always 
readily available. Novel chemical or biochemical methods have been proposed such as 
Edman degradation or MS analysis with extracts from FFPE tissues; however, these 
methods reported so far require sophisticated sample preparation procedures or large 
amounts of starting materials and are not feasible for wide clinical use 
(131, 248)
. On the 
other hand, sequence variations and PTMs in some amyloidogenic precursor proteins 
may be critical factors for the fibrillogenesis process, as for TTR 
(80)
. The sequence of the 
amyloidogenic LC protein is patient-specific. As a result, it is necessary not only to 
classify the amyloid protein but to determine the exact sequence, including the PTM 




F10-118 is an abdominal fat aspirate sample from a patient clinically diagnosed 
with AL-λ amyloidosis. For this case, there was no bone marrow sample available for 
study, making it impossible to derive the cDNA sequence information for the 
amyloidogenic LC. Here, proteins were extracted from the fat sample and the proteome 
was analyzed using 2D SDS-PAGE. Protein sequencing using tandem MS methods was 
carried out on in-gel enzymatic digests of selected spots that were not present in control 
samples, or with signal intensities that were substantially increased compared to levels in 
the control. Eight-six percent of the amino acid sequence of the λLC was determined, as 
well as some of the PTMs present on the protein. The data suggest that this LC is of the 
IGLV1 type.  
This method may be used for tissue samples with amyloid deposits where limited 
sequence information is known beforehand.  
 
2.2 Methods and Experiments 
The general experimental design is a typical gel-based, bottom-up approach 
(Figure 2.1 [a]). For the fat sample, whole protein mass was extracted under reducing 
conditions. The protein extraction was quantified by either the Bradford method or micro 
BCA assay and proteins were separated by 2D SDS-PAGE. Two gels were generated 
with equal protein loading; one was stained to show the protein spots while the other was 
used for Western blot analysis. For the latter purpose, an antibody against epitopes in the 
constant region of λLCs was used. Immuno-reactive spots, as well as spots localized at 




°C for future use. Selected spots were in-gel digested with trypsin or chymotrypsin. The 
desalted digested peptide mixture was first analyzed with a MALDI-TOF MS for PMF 
analysis. Some peaks that corresponded to unknown peptides were selected for tandem 
MS analysis and were dissociated with the MALDI-TOF/TOF instrument. Samples with 
LC peptides were further analyzed by an ESI-LTQ-Orbitrap MS coupled to a nanoUPLC 
with HCD activation. Both the MS and MS/MS data were initially subjected to database 
searches with MASCOT
TM 
(Matrix Science) against Swiss-Prot (2013_01) before the 
results were checked manually. Special attention was paid to unknown peaks which had 
relatively high signal intensities in the MALDI mass spectra.  
LCs of the circulating form were pulled down with direct immunoprecipitation 
(IP) and subjected to 2D SDS-PAGE analysis (detailed further in section 2.2.3); selected 
gel spots were in-gel digested and analyzed by MS and MS/MS. 
Figure 2.1 General experiment designs for a gel-based bottom-up MS analysis of the 





2.2.1 De-identified Patient Profile 
Fat biopsy F10-118 originated from an African-American male who was 58 years 
old at his initial visit to Boston Medical Center. He had mainly soft tissue and renal 
amyloid involvement. The cardiac involvement was equivocal. Amyloid load by CR 
staining in a skin biopsy from the abdominal wall was 2-3+ and in the fat biopsy was 3+. 
Immunofixation electrophoresis (IFE) showed the presence of λ-type monoclonal LC 
proteins in both serum and urine. No corresponding cDNA information was available as a 
bone marrow biopsy was not performed. The fat tissue and serum were stored at -80 °C 
until analysis. Data courtesy of Amyloid research laboratory of Boston University. 
 
2.2.2 Whole Protein Extraction from Fat 
Whole protein extraction from the fat sample followed a detailed protocol 
published elsewhere 
(249)
. First, whole blood components were removed from the tissue 
with three rounds of 0.9% ice-cold NaCl wash, followed by another wash with ultrapure 
water. After each wash, samples were spun at 12,400 rcf for 15 min at 4 ˚C. Both the 
supernatant and red blood cells were discarded. Proteins were extracted under reducing 
conditions with isoelectric focusing (IEF) rehydration buffer (7 M urea, 2 M thiourea, 65 
mM dithiothreitol (DTT) and 4% CHAPS) at a ratio of 300 μL per 100 mg tissue. The 
extracts were centrifuged at 25,000 rcf, 4 ˚C for 1.5 hr; only the middle layer was 
recovered for analysis. Another two centrifugations under the same conditions were 
performed for 30 min each. The protein extractions were combined and quantified with 






2.2.3 Serum Protein Purification 
Purification of the free LC protein from patient serum was carried out with a 
Direct IP kit (Pierce), following both the manufacturer’s instructions and a modified 
published protocol 
(251)
. The antibodies were covalently immobilized to the aldehyde-
activated agarose beads via the amine groups of the lysine side chains through a reductive 
amination reaction. The sheep anti-human free λLC antibody (Bethyl Laboratories, Inc.) 
was first dialyzed against water (4 ˚C, overnight) to remove possible amines in the buffer 
before it was coupled to Aminolink Plus
TM
 agarose beads (380 µg antibody/100 µL bead 
slurry). Excess unbound antibodies were washed away and the remaining reactive sites 
were blocked with sodium cyanoborohydride. One hundred µL of the solution containing 
the Ab-coupled beads was then incubated with 40 µL of serum and 360 µL IP wash 
buffer (25 mM Tris, 0.15 M NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol; pH 7.4) with 
end-over-end mixing (Labquake
TM
, Thermo Scientific) overnight at 4 ˚C, to carry out the 
immuno-reaction. LCs were eluted with the low pH (pH 2.8) elution buffer provided in 
the kit. 
The flow through obtained after coupling of the Ab to the beads, and a solution of 
the precipitated protein were subjected to SDS-PAGE (NuPAGE
®
 bis-Tris precast 4-12% 
gradient gel, 1.0 mm thick, Invitrogen) to check the coupling efficiency and presence of 
LC proteins, respectively.  
Prior to these steps, albumin in the serum sample was removed with an albumin 
depletion kit (Pierce) and quantified using a micro BCA protein assay kit (Pierce) to 




2.2.4 Protein Purification by 2D SDS-PAGE 
The protocol for 2D SDS-PAGE has been published 
(249)
. The protein solution 
was diluted with 100 µL Destreak (Amersham Biosciences) and 6 µL ampholytes (Bio-
Rad), and adjusted with rehydration buffer to a final volume of 300 µL for each gel. This 
mixture was separated on a 17-cm ReadyStrip
TM
 IPG strip (Bio-Rad) (pH 3-10). The IEF 
program was set as follows: 0-1 hr, passive rehydration and sample absorption (10 ˚C), 
no voltage added; 1-9 hr, voltage rapidly increased to and held at 50 V; 9-10 hr, voltage 
rapidly increased to 120 V; 10-10.5 hr, voltage rapidly increased to 300 V; 10.5-13.5 hr, 
voltage linearly increased to 3500 V; in another 10 min, voltage rapidly increased to 5000 
V; finally, voltage set to rapidly increase to and held at 8000 V (although the real value 
depended on the salts in the sample). The program was stopped manually after obtaining 
67,000 V-hrs. The temperature was maintained at 16 ˚C, if not otherwise indicated.  
The IEF strip was incubated with equilibration buffer I (6 M urea, 0.375 M Tris-
HCl, 2% SDS, 20% glycerol and 2% (w/v) DTT) and equilibration buffer II (6 M urea, 
0.375 M Tris-HCl, 2% SDS, 20% glycerol and 2.5% (w/v) iodoacetamide) at room 
temperature for 25 min and 20 min, respectively. The treated strip was then overlaid on a 
1.00 mm thick Tris-glycine gel (with a gradient of 8-16%, Jule Inc.). The gel was run 
with a constant current set in two steps, first at 32 mA for 30 min, before a switch to 48 
mA. After the second dimensional separation, the gel was washed and stained with a 
Proteosilver
TM
 Plus Silver Stain Kit (Sigma Aldrich) or Coomassie GelCode blue 
(Thermo Scientific). Spots of interest were excised with 100 µL wide orifice pipet tips 






The tissue extract and the albumin-depleted serum sample were directly analyzed 
by 2D gel electrophoresis as described above. Proteins from the IP reaction were first 
dialyzed overnight at 4 
o
C, against ultrapure water in a dialysis cassette with molecular 
weight cut-off (MWCO) of 3.5 kDa (Pierce). 
 
2.2.5 Western Blotting Analysis 
Instead of being detected in the PAGE gel via a staining process, proteins were 
transferred from the gel to a PVDF membrane using a semidry electrophoretic method 
(TransBlot
TM
, Bio-Rad). Amyloid LC proteins were probed with a polyclonal rabbit anti-
human Ig λLC antibody (Dako, 1:1000 dilution) followed by an alkaline phosphatase-
conjugated polyclonal goat anti-rabbit secondary antibody (Dako, 1:5000 dilution). 
 
2.2.6 In-Gel Enzyme Digestion 
In-gel enzymatic digestion of selected spots on 2D gels followed a published 
protocol 
(252)
. Briefly, gel plugs were first destained with the destaining solution in the 
silver stain kit and sequentially washed with three solutions, 100 mM NH4HCO3, 100 
mM NH4HCO3/50% ACN and 100% ACN; each extraction was repeated three times. 
After the final ACN wash, the gel plugs were completely dried on a SpeedVac (Savant 
SC110A, ThermoFisher Scientific) before being rehydrated in the digestion solution of 
50 mM NH4HCO3/5% ACN containing either Trypsin Gold (Promega) or chymotrypsin 
(Sigma-Aldrich); a 1:10 enzyme-to-substrate weight ratio was used. Digestion was 




trifluoroacetic acid (TFA). Peptides were extracted once with 20 mM NH4HCO3, twice 
with 1% TFA/ 50% can, and finally with 100% can in 20 min treatments for each. 
Supernatants were pooled and dried with a SpeedVac for future use. 
One tryptic peptide digestion mixture was further digested overnight at 37 ˚C with 
endoprotease GluC (Promega) in 50 mM NH4HCO3 at a 1:50 enzyme-to-substrate weight 
ratio. The product mixture was dried in a SpeedVac before being analyzed. 
 
2.2.7 Instrumentation and Data Analysis 
Samples were always desalted with a C18 ZipTip
®
 (Millipore) before being 
introduced into any of the mass spectrometers.  
MALDI-TOF MS spectra were recorded with a Reflex IV™ MS (Bruker 
Daltonics). MALDI LIFT-TOF/TOF analysis was performed with an ultrafleXtreme™ 
MS (Bruker Daltonics). Both instruments were operated in the positive ion mode and 
calibrated externally with 2 pmol of peptide calibration standard II (Bruker Daltonics) for 
the MS mode prior to use. Samples were typically resuspended in 50% ACN/0.1% TFA 
to a final concentration of 0.01-1 pmol/µL, with 10 mg/ml DHB as the matrix. 
Nano-ESI tandem MS analysis was also performed with an LTQ-Orbitrap XL™ 
MS (Thermo Fisher Scientific) coupled to both a nanoACQUITY UPLC
®
 system 
(Waters) and an Advion TriVersa NanoMate™ instrument (Advion Biosciences). This 
system was capable of analyzing as little as 100 fmol of the peptide digests. Each sample 
was resuspended in 98% buffer A (1% ACN/99% H2O/0.1% FA) and 2% buffer B (99% 




follows: 1-3 min, 98% buffer A; 3-43 min 98-95% buffer A; 43-52 min, 95-60% buffer 
A; 52-53, 60% buffer A; 53-57 min, 60-2% buffer A; 57-60 min, 2-98% buffer A; 60-75 
min, 98% buffer A. The trapping process was carried out on a nanoACQUITY UPLC 2G 
Trap Column (5 µm particle size, 180 µm x 20 mm, Waters) using 98% buffer A and 2% 
buffer B at a flow rate of 4 μL/min for 4 min. The separation was achieved with an 
ACQUITY UPLC BEH C18 column (1.7 µm particle size, 150 µm x 100 mm, Waters) at 
37 
o
C using a flow rate of 0.5 μL/min. Multiple fragmentation methods were performed, 
including CID, HCD and ETD. For CID, the collision gas was argon and the collisional 
energy was 35 eV, followed by detection in the LTQ or the orbitrap. For HCD, the 
collisional energy was 30 eV. For ETD, the reagent was fluoranthene; an activation of 
100 ms was followed by detection in the orbitrap. 
The LTQ ESI positive ion calibration solution (Pierce) was used for mass 
calibration of the FT mass spectra. Calibration of the tandem mass spectra (CID/HCD), 
including the isolation window and activation energy, was performed with 1 µL of 500 
fmol/µL Glu-1-fibrinopeptide B (Glu-Fib, Sigma Aldrich). Both samples were delivered 
directly through the NanoMate™; the Glu-Fib was dissolved in 50% ACN/0.1% FA. 
Data were searched with MASCOT
TM
 (Matrix Science) against the Swiss-Prot 
database (2013_01) with the following choice of parameters: (a) trypsin/chymotrypsin 
digestion with up to three missed cleavages, (b) ± 500 ppm error for MS analysis on the 
MALDI instrument; for data collected from the Orbitrap, ± 5 ppm error for the MS and ± 
0.8 Da error for the MS/MS, and (c) cysteine carbamidomethylation, 




were also checked manually. For de novo sequencing, a string of consecutive amino acid 
residues (the result was more confident if  ≥ 5) were deduced from the spectrum, and the 
short peptide sequence was sent to the basic local alignment search tool (BLAST
®
) to 
search for homologous sequences of human LC proteins (Figure 2.1 [b]). This result was 
used as an attempt to fill gaps between short sequences. This process, together with 
manual interpolation between database assignments, was repeated until the full sequence 
was deciphered.  
 
2.3 Results and Discussion 
2.3.1 Determination of Amino Acid Sequence of Amyloidogenic LC Deposited in 
Fat, F10-118 
Whole proteins were extracted from the fat sample under reducing conditions and 
subjected to 2D SDS-PAGE gel analysis (Figure 2.2). Western blotting analysis against 
the Ig λLC constant region detected spots: 12-14, 16-20 and 22-24. These proteins had 
apparent molecular weights ranging roughly from 22-30 kDa. Spots located on the left 
(acidic) part of the gel, with lower molecular weights, between 15-20 kDa, appeared to be 
LC fragments but were not flagged by the Western blot analysis (probably because they 
were lacking epitopes recognized by antibodies directed at the constant region, CL as 
discussed below). 
Selected spots (labeled in Figure 2.2) were in-gel digested with trypsin followed 
by MS peptide mass fingerprinting and tandem MS analysis. Figure 2.3 shows selected 




third 2D SDS-PAGE gel was run and spots were labeled in the same fashion. Spots 16-18 
were cut and in-gel digested with chymotrypsin. The MALDI mass spectrum of the 
chymotryptic peptide mixture from spot 18 is shown in Figure 2.4.   
A MASCOT
TM
 search of the peak list from the MALDI-TOF mass spectrum of 
tryptic peptides derived from spot 18 returned a top hit for the Ig λ2 CL region (Figure 
2.3). This was consistent with the results obtained from the IFE experiment. Peptide [C 
23-29] ADSSPVK was detected only with LC-MS/MS analysis. Tryptic and 
chymotryptic peptides derived from spots 16-20 were all analyzed by LC-MS/MS with 
CID activation (with detection in the ion trap) and returned full coverage of the Ig λ2 CL 
region. In addition to the peaks corresponding to tryptic peptides from the constant 
region, the MALDI-TOF MS spectrum for spot 18 also included some other peaks 
common to the mass spectra of other spots, with [M + H]
+
 peaks observed at m/z 841.51, 
1813.92, 1831.96 and 3900.75, values which were later confirmed to correspond to 
peptides derived from the VL. A peak that could be assigned to a variable region tryptic 
peptide, with [M + H]
+
 m/z 2338.19, was observed in the mass spectra of  all spots other 





Figure 2.2 The region containing proteins with MWs > 15 kDa in the 2D SDS-PAGE 
of 87.5 μg whole protein extracts from a subcutaneous fat biopsy (F10-118), 
separated under reducing conditions. The gel was silver stained. The gel area in the 





Figure 2.3 (following page) MALDI-TOF mass spectra of in-gel tryptic peptides 
from five spots as labeled in Figure 2.2. The sequence coverage of Ig λ2 chain C 
regions for spot 18 of this particular MALDI spectrum is shown underlined. Peptide [C 
23-29] ADSSPVK was detected in the LC-MS/MS analysis. Peaks labeled in bold were 
later confirmed to be variable region peptides. Peptide [C 60-79] modified by 
deamidation (“*”),pyroglutamate formation (-NH3) and tryptophan oxidation (+W(O)). 














Figure 2.4 MALDI-TOF mass spectrum of in-gel chymotryptic peptide mixture 
from spot 18 in Figure 2.2. The numbering is based on the sequence assignment in 
Figure 14 [b]. The peak with [M + H]
+
 m/z 1001.55 can be assigned to a peptide derived 
from the protease. The same asparagine residue (protein residue N173 = N62 of the 
constant region, as labeled in Figure 2.3) was deamidated, as indicated in peaks [M + H]
+
 
m/z 2538.16 and 3017.47. Peptide [38-48] contains N-terminal pyroglutamate. 
 
Manual interpretation of the LC-MS/MS spectrum of [M + 2H]
2+
 m/z 907.4373 
(corresponding to [M + H]
+
 m/z 1813.8668), with HCD activation if not otherwise 
specified, was consistent with the peptide sequence NYVSWYQQFPGTAPR; this 
sequence was later assigned VL (32-46) (Figures 2.5 [a] and 14 [b]). ESI-LC-MS analysis 





the peptide YVSWYQQFPGTAPR. This peak gave a y ion series from y2 to y13 upon 
activation (Figure 2.5 [b]) and this result contributed to the unambiguous assignment of 
the amino acid sequences of “NY” and “PGT”. Analysis of spot 6 led to the sequence 
determination of several peptides containing the common sequence, 
NYVSWYQQFPGTAPR (Figure 2.5 [b]). When all this information was combined, the 
amino acid residue 31 could be confidently identified as tyrosine (Y). Tentative 
assignments were given for the regions containing amino acids (23-30) based on the 
peptide molecular weights and homology to the established CL domain LC sequence 
(Figure 2.14). The longest peptide ([M + H]
+
 m/z 2666.2278) most likely corresponds to 






Figure 2.5 Tandem MS analysis of peptides [X-46]. [a] ESI-HCD-MS/MS mass 
spectrum of a doubly charged tryptic peptide [M + 2H]
2+
 m/z 907.4373, which was 
thereby revealed as a variable region peptide VL (32-46). More fragmentation patterns of 
tryptic peptides from both spot 11 (labeled with “*”) and spot 6 are shown in [b]. 
Tentative assignments are given for amino acids [23-30] based on both the molecular 





Manual interpretation of the LC-MS/MS spectrum of [M + 4H]
4+
 m/z 458.9874 
(corresponding to molecular ion [M + H]
+
 m/z 1832.9261) revealed the VL peptide (47-
62) sequence, LLIHDNDNRPSGLPDR, with N52 deamidated as evidenced by mass 





 was shifted. Cleavage between P56 and S57 was observed in the 
tandem spectra of other charge states of the same peptide. No differentiation between the 
isomeric leucine (L) and isoleucine (I) residues was possible with the methods used here. 
Tentative assignments of these two residues were based on the homologous LC sequence 
discussed below. Analysis of a tryptic peptide peak common to the mass spectra of spots 
13, 22, 8 and 10 in Figure 2.3 ([M + H]
+
 m/z 2338.19 in spot 13) indicated a peptide with 
[M + 4H]
4+
 m/z 585.3025 (Figure 2.7) containing one undigested trypsin site (VL, 47-67), 
and the sequence, LLIHDNDNRPSGLPDRFSGSK. Fragmentation of a chymotryptic 
peptide [64-74] gave efficient cleavages between of all the backbone amide bonds 






Figure 2.6 ESI-HCD-MS/MS spectrum of a multiply charged tryptic peptide 
[corresponding to M + 4H]
4+
 m/z 458.9874 ([M + H]
+
 m/z 1832.9261). This peptide 
was deduced to be a variable region peptide VL (47-62). The asparagine (N) residue 
labeled in bold was deamidated. Both y and b ions containing this residue were mass-
shifted compared with the value expected for the unmodified residue, as indicated by “*”. 
The assignments of leucine (L) and isoleucine (I) were tentative, and were based on the 










































































































































































































Determination of the amino acid sequence for the long peptide with [M + H]
+
 m/z 
3900.75 (spot 18, Figure 2.2) was challenging, but finally characterized as a VL region 
peptide containing part of the joining region (VL, 68-98 and JL, 99-106). The sequence of 
this fragment was SGTSASLGITGLQTGDEADYYCGTWDSSLNAGVFGGGTK. 
Tandem MS with HCD fragmentation of the [M + 3H]
3+
 precursor ion at m/z 1300.9244, 
generated only singly charged y ions which covered a small portion of the total sequence, 
limited by  automatic setting of a detection range up to m/z 2000 (Figure 2.9). Although 
ions with lower m/z were not transmitted, detection of the higher m/z product ions in the 
orbitrap following CID activation yielded a rich spectrum containing both singly and 
doubly charged fragment ions. The more complete cleavages provided a better sequence 
coverage ([M + 3H]
3+
 m/z 1300.9244, Figure 2.10). Spot 11 happened to provide a 
spectrum for a truncated form of this fragment ([M + 2H]
2+
 m/z 907.4125, Figure 2.11) 
corresponding to the peptide resulting from cleavage between Y88 and C89. 
Endopeptidase GluC was applied to the purified in-gel tryptic mixture, derived from spot 
7, to produce shorter peptides for MS analysis (Figure 2.12). ETD fragmentation of the 
doubly charged ion, observed at m/z 797.3844 (corresponding to [M + H]
+
 m/z 1593.78 in 
Figure 2.12 [a]), yielded efficient cleavages of peptide VL (68-84); cleavage was noted 
even between the first three amino acids SGT (Figure 2.12 [b]), even though both HCD 







































































































































































































































Figure 2.11 ESI-HCD-MS/MS mass spectrum of the peptide (89-106), [M + 2H]
2+
 
m/z 907.4125 (corresponding to [M + H]
+









Figure 2.12 Tryptic peptides derived from spot 7 in Figure 2.2 after digestion with 
GluC. The MALDI-TOF mass spectrum is shown in [a]. ETD activation of doubly 






Manual interpretation of the LC-MS/MS spectrum of [M + 2H]
2+
 m/z 421.2605 
(corresponding to [M + H]
+
 m/z 841.5132) yielded the amino acid sequence of the other 
part of the joining region and the first four residues of the constant region (JL,107-111 
and CL, 112-114), VTVLGQPK (Figure 2.13). 
 
Figure 2.13 ESI-HCD-MS/MS mass spectrum of the peptide (107-114), [M + 2H]
2+
 
m/z 421.2605 (corresponding to [M + H]
+
 m/z 841.5132).  
 
The derived LC sequence excluding the constant region was submitted to 
IMGT/DomainGapAlign 
(253, 254)
. Leucine and isoleucine residues were not differentiated; 
both were identified as L. The species was chosen as Homo sapiens (human) and for 






51*01 and IGLJ2*01 for the variable region and the joining region, respectively (Figure 
2.14 [a]). Based on the search results, L and I were re-assigned and other amino acids 
different from IGLV1-51*01 are labeled underneath these data. A gap has been left for 
the N-terminal residues; the numbering of the amino acids determined with de novo 
sequencing is shown in Figure 2.14 [b]. In total, eighty-six percent of the amino acid 
sequence of this λLC has been determined by MS de novo sequencing analysis using 






Figure 2.14 Summary of the derived LC sequence. The derived LC sequences of the 
variable and joining regions were submitted to IMGT/DomainGapAlign and returned top 
hits of IGLV1-51*01 and IGLJ2*01 (sequence shaded) [a]. The derived sequence for LC 
extracted is labeled as F10-118, also shown in [b], from which the numbering used 
throughout the paper has been taken. The assignments of the underlined amino acids 
SGSSSNIG (Figure 2.5) and the differentiation of leucine and isoleucine residues were 
based on IGLV1-51. 
 
The full N-terminal sequence of this extracted amyloidogenic LC was not 
deduced. Around fourteen percent of the whole sequence was still not obtained mainly 
[a] 
         FR1-IMGT            CDR1-IMGT        FR2-IMGT      CDR2-IMGT                    
          (1-26)              (27-38)         (39-55)        (56-65)                     
       A             B           BC         C        C'        C'C"  
    (1-15)        (16-26)     (27-38)    (39-46)   (47-55)   (56-65)  
——————————————> ——————————>              ———————> ————————>  
1        10  15 16    23 26 27        38 3941  46 47     55 56      65  
|........|....| |......|..| |..........| |.|....| |.......| |........|  
QSVLTQPPS.VSAAP GQKVTISCSGS SSN....IGNNY VSWYQQLP GTAPKLLIY DN.......N Z73661,IGLV1-51 
............... ........SGS SSN....IGYNY VSWYQQFP GTAPRLLIH DN.......D F10-118 
                                     Y         F      R   H          D  
 
                    FR3-IMGT                CDR3-IMGT     FR4-IMGT 
                    (66-104)                (105-117)     (118-128) 
   C"         D           E          F          FG            G 
 (66-74)   (75-84)     (85-96)    (97-104)  (105-117)     (118-128)       
————————> —————————> ———————————> ———————>          
66     74 75      84 85  89    96 97   104 105 11112 117 118     128 
|.......| |........| |...|......| |......| |.....||....| |.........| 
KRPSGIP.D RFSGSK..SG TSATLGITGLQT GDEADYYC GTWDSSLSA  VV FGGGTKLTVL.  Z73661,IGLV1-51 
NRPSGIP.D RFSGSK..SG TSASLGITGLQT GDEADYYC GTWDSSLNA  GV FGGGTKVTVL.  F10-118 




  1                         SGSSSNIG YNYVSWYQQF PGTAPRLLIH  
 51 DNDNRPSGIP DRFSGSKSGT SASLGITGLQ TGDEADYYCG TWDSSLNAGV  
101 FGGGTKVTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 
151 AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT  







those residues at the N-terminal part of the protein. For this fat sample, spots 16-20 were 
picked up by Western blotting analysis using a polyclonal antibody against epitopes in 
the λLC constant region. Considering their positions on the SDS PAGE gels, it was 
highly possible that these spots contained full-length LC proteins. The difference between 
their apparent molecular weights, namely around 30 kDa, and the expected 25 kDa for a 
typical LC protein might be due to the presence of some modifications which cause a 
different migration behavior from the standard proteins. However, even with spot 18, 
peptides containing the first 31 amino acids of the variable region could not be sequenced 
with the method used here. There could be several possibilities: (1) the N-terminal 
peptides were too heavily modified to be de novo sequenced manually, (2) these stretches 
of peptides were simply not there, due to (non-)enzymatic degradation that may have 
occurred before or after protein deposition, (3) the sample handling process might not be 
able to preserve the integrity of the N-terminus, or (4) the peptides generated from 
protease treatment might not be amenable to the sequencing method used in this study, 
i.e. peptides either too short or too long were not well retained on the reversed-phase 
column or not well ionized with MALDI/ESI. Still, two tryptic peptides ([M + H]
+
 m/z 
1636.12 and 1727.72 (Figure 2.3), and two chymotryptic peptides ([M + H]
+
 m/z 1523.81 
and 1737.37 (Figure 2.4) of spot 18 could not be identified because of inadequate 
sequence coverage from the observed fragment ions. It is possible that these peptides 
arise from truncation or other modifications. 
Leucine and isoleucine residues were not differentiated here. In theory, tandem 




since different w ions would be generated for these two residues 
(224, 255)
. However, 
experiments with nanoESI-FT-MS/MS analysis of the tryptic peptide mixture did not 
show satisfactory results due to the low concentration and, more importantly, the low 
isolation efficiency of the precursor ions. Considering the fact that chymotrypsin could 
cleave the peptide bond following a leucine, but not an isoleucine residue, makes  it seem 
likely that amino acids 48, 74, 110, 129, 136 and 182 were leucine not isoleucine 
residues. 
 
2.3.2 Characterization of Post-Translational Modifications 
Amyloidogenic LCs extracted from this fat sample were heavily truncated. In 
Figure 2.3, in order of decreasing apparent molecular weight, the abundances of the peaks 
for constant region peptides, e.g., C 4-22 m/z 1986.01, diminished. The serially truncated 
products from this peptide appeared at m/z 1857.93 [C 4-21], 1743.87 [C 4-20], 1672.84 
[C 4-19], 1544.78 [C 4-18], and 1431.70 [C 4-17] in the spectra of Spots 8 and 10. These 
assignments were confirmed by tandem MS data. HCD fragmentation of the doubly 
charged peptide [C 4-17] ([M + H + Na]
2+
 m/z 727.3439) is shown in Figure 2.15. We 
could not exclude the possibility that, for this specific sample, both the variable and 
constant regions of the Ig λLC were trimmed; thus, the proteins deposited in each spot 







Figure 2.15 ESI-HCD-MS/MS mass spectrum of doubly charged peptide CL (115-





PTMs, other than truncations, were also found. Asparagine 52 (N52) was partially 
deamidated, as confirmed by data shown in Figure 2.6; this modification was also found 
on N173, as was determined from the peak observed for a tryptic peptide in spot 18 ([C 
60-79], Figure 2.3) and two peaks for chymotryptic peptides in spot 18 ([153-176] and 
[153-181], Figure 2.4). Deamidation of asparagine is a non-enzymatic process that occurs 






isoaspartic acid (Figure 2.16) 
(221, 256)
. Formation of either product will change the local 
charge state of the protein and may help the fibrillogenesis process. 
 
Figure 2.16 Deamidation of an asparagine residue. 
 
Pyroglutamate was formed from an N-terminal glutamine residue, Q171, in the 
tryptic peptide (171-190) (C 60-79 in Figure 2.3) and also at Q38 in the chymotryptic 
peptide (38-48) (Figure 2.17). This type of modification could also occur non-
enzymatically in vitro. 
 
 








In Figure 2.18 [a] (enlarged from Figure 2.3, spot 18), tryptic digestion of spot 18 
showed a group of peptide peaks, which compared to the peak for peptide [176-190], had 
+4 u, +16 u, +32 u, and +48 u mass shifts, respectively. Further analysis with LIFT 
fragmentation on a MALDI-TOF/TOF instrument (Figure 2.18 [b, c]) proved that these 
were serially modified oxidation products of a tryptophan (W) residue located in the 
constant region (W189); oxidation products included kynurenine (+4 u), hydroxy-Trp 
(+16 u), N-formylkynurenine (+32 u), and hydroxy-N-formylkynurenine (+48 u) whose 
chemical structures are shown in Figure 2.19. Oxidation of W189 may be due to reactive 
oxygen species (ROS) or may simply have resulted from the sample handling process 
which involves gel separation 
(257)
. There are four tryptophan residues in this LC protein, 
W36, W92, W152 and W189. The first two are in the VL domain while the others are in 
the CL region. Although oxidative modifications of W36, W92, and W152 were also 
detected in ESI-LC/MS, the oxidized species of W189 were more readily detected in a 
MALDI-TOF mass spectrum. This might be due to a higher ionization efficiency of 
peptides containing W189 or that this residue was more susceptible to modification by 
oxidation as it is located at an exposed position on the surface of the LC protein. 
However, under conditions used for the experiments, the protein should have lost its 
tertiary structure, so selective in vitro oxidation seems unlikely. It has been reported that 
oxidation of one critical tryptophan residue of the egg-white lysozyme by ozone may 
inactivate this enzyme 
(258)
. The exact role of tryptophan oxidation in LC fibril formation 









































































































































Figure 2.19 Oxidative degradation products of tryptophan residue observed in Ig 
LC F10-118. [a] Kynurenine (+ 4 u), [b] hydroxy-Trp (+16 u), [c] N-formylkynurenine 
(+ 32 u), and [d] hydroxy-N-formylkynurenine (+ 48 u). 
 
2.3.3 Characterization of Serum LC Proteins 
A serum sample was available for the patient from whom the fat aspirate, F10-
118, was collected. After depletion of most of the albumin in the serum sample, 400 μg of 
the remaining proteins were separated by 2D SDS-PAGE (Figure 2.20 [a]). Free LCs 
pulled-down from 40 μL serum were also subjected to the gel analysis (Figure 2.20 [b]). 
Spots in dashed circles of both gels were in-gel digested with trypsin and MS-analzyed, 
and these were found to contain LC peptides. The gel spots resulting from the serum 
sample had apparent molecular weights similar to those observed for spots 16-20 in the 
fat tissue (Figure 2.2). No obvious LC fragments were observed in the serum sample 
(Figure 2.20) at the lower part of the gel. Truncated forms of the LC protein might be not 
present in the circulation, at too low concentrations to be detected with the method used 
here, or present as a complex with other blood components. It must be pointed out that 






with the antibody raised against the CL domain. Oxidation of W189 was also observed in 
the MALDI spectra. 
 
Figure 2.20 2D SDS-PAGE gels of serum LCs from the same patient who provided 
fat biopsy F10-118. Samples loaded were: [a] 400 μg albumin-depleted proteins and [b] 






 It is quite possible that abbreant/truncated forms of LC proteins are produced at 
the deposition sites instead of being the result of synthesis defect. Investigation and 
discussion of additional serum samples from patients with AL amyloidosis are available 
in Chapter 3. 
 
2.4 Conclusions 
This chapter described the de novo sequencing of LC proteins extracted from a fat 
aspirate (F10-118) using 2D SDS-PAGE gel separation, in-gel protein digestion, and MS-
based characterizations. After different MS types of instrumentation and various 
fragmentation methods were applied, eighty-six percent of the LC protein sequence was 
deduced. PTM information was derived at the same time. It is highly possible that both 
full-length LCs and LCs with truncated C-termini were deposited while only intact LCs 
were present in the circulation. Other PTMs observed included deamidation of asparagine 
residues, pyroglutamate formation from N-terminal glutamines, and oxidation of 
tryptophan residues.  
This work demonstrates that mass spectrometry is a powerful tool for amyloid 
protein sequencing and characterization, and thus, is useful in the diagnosis, prognosis, 
and treatment of amyloidosis diseases. The method used here is very sensitive since 






Comparison of IGLV6 Immunoglobulin Light Chains from Kidney, Serum and 
Urine Samples of Five Patients 
 
3.1 Introduction 
Several factors are believed to be important for the pathogenesis of AL 
amyloidosis. As with other protein misfolding-aggregation disorders, AL may result from 
a perturbation of the normally stable structure-function relationship of LC proteins. As 
discussed in Chapter 1, sequence variations, PTMs, and accessory molecules may be 
important factors for the formation of AL amyloid fibrils. However, the amyloidogenic 
LC sequence is patient-specific with great variability, especially in the VL domain of the 
protein, making the investigations complicated. There is not yet conclusive information 
about the structural requirements for in vivo fibrillogenesis of these proteins.  
For deposited LC amyloid fibrils, fragments with processed C-terminals are 
commonly found, although the occasional presence of full-length LCs or LCs with 
processed N-terminals has also been reported 
(64, 90, 91)
. It is not clear whether the 
proteolytic process happens before or after fibrillogenesis, or at both stages. The 
fragments may play an important role in fibril formation or may just occur as metabolic 
products from the amyloid fibrils.  
Immunohistochemical approaches are the major means used to probe the 




limited by the availability of antibodies, whose production usually demands much effort 
and high cost. In the current study, a combination of 2D SDS-PAGE and MS-based 
methods were used to interrogate LCs in kidney, serum, and urine samples from five 
patients with IGLV6 LC amyloidosis, to compare the PTMs of LCs from different 
sources with a focus on truncations. The λ6 subfamily of LC proteins has been described 
almost exclusively in patients with AL 
(75-78)
. With our method, we determined that full-
length LC was the only form found in the serum. While a small amount of full-length LC 
was present in the kidney autopsy of one patient, tissue deposits of amyloid from all five 
patients had N-terminal LC fragments. This finding indicates that, instead of aberrant 
protein production, LC proteins may be processed in the organ. Interestingly, the two 
available urinary LC samples showed both full-length proteins and C-terminal fragments. 
 
3.2 Methods and Experiments 
A summary of the general experimental design for these studies follows. The 
entire protein fraction was extracted from the kidney tissues under reducing conditions. 
For serum samples, albumin was removed or free LC proteins were immunoprecipitated. 
Urine samples were dialyzed to remove salts and other small molecules. The treated 
samples were then separated on 2D SDS-PAGE gels. Spots of interest were cut, in-gel 
digested, and characterized by MS-based methods. Please refer to Chapter 2 for details of 






3.2.1 De-identified Patient Profiles 
Biological samples were obtained from a group of five patients with AL 
amyloidosis, each featuring the overproduction of a monoclonal IGLV6 LC. The sample 
summary is presented in Table 3.1. All five patients were referred to the Amyloidosis 
Center at Boston Medical Center for evaluation of amyloid disease and consented to 
participate in a research study under a protocol approved by the Institutional Review 
Board at Boston University Medical Center consistent with the Declaration of Helsinki. 
Serum was collected at clinical visits. Patient urine samples were collected over a 24 hr 
interval in containers with approximately 0.01% EDTA and 0.02% NaN3 as preservative 
agents. All patients had a plasma cell dyscrasia demonstrated by the presence of λ clonal 
plasma cells in the bone marrow and/or a monoclonal Ig λLC in serum and/or urine 
detected by immunofixation electrophoresis (IFE). All patients had renal involvement 
manifested by proteinuria; none had elevated creatinine or was on dialysis. Kidney tissue 
samples were obtained during postmortem examination and kept frozen at -80 °C until 
MS analysis. Tissue from each of the five autopsied kidneys was formalin-fixed and 
paraffin embedded; tissue sections were stained with Congo red and all showed apple 
green birefringence by polarized light microscopy. The amyloid load indicated by Congo 
red staining in kidney tissue varied from trace amounts (1+) to high abundance (4+). 
Bone marrow aspirate samples were also collected at the time of patient evaluation for 





Kidney autopsies and sera were obtained from all five patients while two urine 
samples were available for patients, 2001021 and 2003118. 
3.2.2 Sample Preparation and Analysis 
VL Gene Usage 
In all sequences, the IGLV6-57*01 germline donor gene was used in IGL gene 
rearrangement. Samples 2001021 and 2000075 used the IGL constant region gene 1 
(IGLC1) and IGLC2, respectively, and samples 2003118, 2005135, and 2001095 used 
the IGLC3 gene. In sample 2005135, the replacement of arginine with asparagine, and 
the deletion of a serine residue compared to the germline gene, created a potential N-
glycosylation site (residue position Asn194). LC sequences deduced from cDNA 
information can be found in Figure 3.1. Data courtesy of Amyloid research laboratory of 
Boston University. 
 
Table 3.1 Sample summaries.* (Data courtesy of Amyloid research laboratory of 
Boston University.) 
 Serum IFE Urine IFE Amyloid 
Load (CR) 
Dialysis IGLC Predicted N-
Glyco site 
2000075 FLC FLC 1+ No IGLC2 None 
2001021 FLC FLC 2+ No IGLC1 None 
2003118 FLC FLC 3+ No IGLC3 None 
2001095 None FLC 3+ No IGLC3 None 




*FLC: free LC. 
 
2000075 
   1-50 NFMLT QPHSV SESPG KTVTI SCTRS SGSIA SNYVQ WYQQR PGRSP TVVIY  
 51-100 EDNER PSGVP DRFSG SIDSS SNSAS LTISG LKTED EADYY CQSYD SNIHM  
101-150 IFGGG TKLTV LGQPK AAPSV TLFPP SSEEL QANKA TLVCL ISDFY PGAVT  
151-200 VAWKA DSSPV KAGVE TTTPS KQSNN KYAAS SYLSL TPEQW KSHRS YSCQV  
200-217 THEGS TVEKT VAPTE CS 
 
2001021 
   1-50 NFMLT QPHSV SESPG KTVTI SCTRS SGSIV TNYVH WYQQR PGSLP TTVIY  
 51-100 EDNQR PSGVP DRFSG SIDSS SNSAS LTISG LKTED EADYY CQSYD SDSYV  
101-150 FGTGT KVTVL GQPKA NPTVT LFPPS SEELQ ANKAT LVCLI SDFYP GAVTV  
151-200 AWKAD GSPVK AGVET TKPSK QSNNK YAASS YLSLT PEQWK SHRSY SCQVT  
200-217 HEGST VEKTV APTEC S 
 
2003118 
   1-50 NFMLT QPHSV SESPG KTVAI SCTRS SGSIA SDYVQ WYQQR PGSSP TLVIY  
 51-100 EDNQR PSGVP DRFSG SIDSS SNSAS LTISG LQTMD EADYY CQSYN NNNLW  
101-150 VFGGG TKLTV LGQPK AAPSV TLFPP SSEEL QANKA TLVCL ISDFY PGAVT  
151-200 VAWKA DSSPV KAGVE TTTPS KQSNN KYAAS SYLSL TPEQW KSHKS YSCQV  
200-217 THEGS TVEKT VAPTE CS 
 
2001095 
   1-50 NFMLT QPHSV SESPG KTVTI SCTRS SGSIA STYVQ WYQQR PGSAP TNVIF  
 51-100 EDNER PSGVP DRFSG SIDSS SNSAY LTISG LKTED EADYY CQSYG TNNWV  
101-150 FGGGT KLTVL GQPKA APSVT LFPPS SEELQ ANKAT LVCLI SDFYP GAVTV  
151-200 AWKAD SSPVK AGVET TTPSK QSNNK YAASS YLSLT PEQWK SHRSY SCQVT  
200-217 HEGST VEKTV APTEC S 
 
2005135 
   1-50 SFMLT QPHSV SESPG KTVTI SCTRS SGSIV SNYVQ WYQQR PGNSP NNVIY  
 51-100 DDNQR PSGVP DRFSG SIDSS SNSAS LTISG LKTED EADYY CQSYD SANQG  
101-150 VFGGG TKLTV LGQPK AAPSV TLFPP SSEEL QANKA TLVCL ISDFY PGAVT  
151-200 VAWKA DSSPV KAGVE TTTPS KQSNN KYAAS SYLSL TPEQW KSHNY SCQVT  









Figure 3.1 LC sequences deduced from cDNA information. (Data courtesy of 
Amyloid research laboratory of Boston University.) 
Urine Sample Pretreatment 
The urine sample was retrieved as quickly as possible and immediately dialyzed 
against deionized water through five separate changes; the dialysis membrane tubing had 
a MWCO of 6000-8000 Da (Spectrum Laboratories). The dialyzed sample was then 
lyophilized and stored at -20 
o
C for future use. Sample preparation courtesy of Amyloid 
research laboratory of Boston University. 
Protocols for whole protein extraction from kidney tissue and protein purification 
from serum have been described in Chapter 2. Protein concentrations in the tissue extract 
were measured with RC DC
TM
 Protein Assay (Bio-Rad). 
In-gel digestion of selected spots was performed with Trypsin Gold, with the aid 
of ProteaseMAX
TM
 Surfactant (both from Promega) at 50 
o
C for 1 hr. The later reagent 
helped to achieve a more complete digestion and elution of the larger peptides without 
additional extraction steps. Peptides were collected from the supernatant after 
centrifugation at 16,000 rcf for 10 min.  
MALDI-TOF mass spectra were recorded with ultrafleXtreme™ MS (Bruker 
Daltonics). ESI-tandem MS analysis was performed with an LTQ-Orbitrap XL™ MS 
(Thermo Fisher Scientific) coupled to both a nanoACQUITY UPLC
®
 system (Waters) 
and an Advion TriVersa NanoMate™ system (Advion Biosciences) with CID (detection 
in the LTQ) or HCD activation (detection in the Orbitrap). Data were either searched 




(2013_01) or with the SEQUEST search function against a homemade database 
containing all five DNA-predicted LC protein sequences; the results were checked 
manually. Choice of search parameters was the same as detailed in Chapter 2. 
 
3.3 Results and Discussion 
3.3.1 Characterization of Deposited LCs in Kidney Autopsies 
Whole protein samples from kidney autopsies 2000075K, 2001021K, 2003118K, 
2001095K and 2005135K were extracted into the IEF rehydration buffer and separated 
by 2D SDS-PAGE under reducing conditions (Figure 3.2). At first glance, SDS-PAGE 
gels of tissues 2000075K, 2001095K and 2005135K showed spots spreading across the 
gel, while 2001021K protein extracts were more concentrated in the lower part of the gel. 
Separation of 600 µg protein extraction from sample 2003118K on the 2D gel showed 
only smears at the lower molecular weight end after Coomassie blue staining (gel picture 
is not shown). It is possible that the proteins are highly degraded in this autopsy sample. 
Based on our previous experience with analysis of LCs deposited in fat biopsy 
samples (F10-118 in Chapter 2 and reference 
(249)
), immunohistochemical analysis using 
polyclonal antibodies directed at the CL region of λLC was not performed; instead, spots 
with apparent molecular weights under 30 kDa were selected from each SDS-PAGE gel 
and these were in-gel digested with trypsin prior to analysis of the resulting peptides by 
MALDI-TOF MS and LC-MS/MS. 
Selected gel spots corresponding to proteins with higher molecular weights and/or 




identified in sample 2001021K and labeled in Figure 3.2 [b] are collagen αI, tropomyosin 
β, complement factor H-related protein 1 and α and β hemoglobin. SAP co-localized with 
the full-length LC at spot 23. This protein has been reported to have a possible role in 




Figure 3.2 2D SDS-PAGE gels of proteins extracted from kidney tissues. [a] 
extraction from 2000075K (525 μg) and [b] extraction from 2001021K (1255 μg) were 





from 2001095K (648 μg) and [d] extraction from 2005135K (803 μg) were loaded. Spots 
in dashed squares contained LC sequences. 
Patient monoclonal LC protein sequences were deduced from bone marrow- 
derived cDNA sequences. The trypsin digestion products from each amyloidogenic LC 
protein were calculated with GPMAW 6.0 (Lighthouse data). Spots found to contain 
tryptic peptide peaks that corresponded to the amyloidogenic LC deduced sequences have 
been marked with dashed rectangles in Figure 3.2. Whereas the protein extracts from 
three of the kidney samples (2000075K, 2001095K, and 2005135K) showed relatively 
small amounts of LC fragments generally with apparent molecular weights of 
approximately 15 kDa, the proteins recovered from 2001021K were almost exclusively 
composed of full-length LC (spots 23-25, apparent molecular weight around 25 kDa, 
confirmed by MS analysis) and LC fragments (Figure 3.3). All five kidney-deposited LCs 
had the same tryptic peptide, TVAPTECS, at the C-terminus. As this terminal peptide is 
an acidic peptide, it is difficult to detect by MS in the positive-ion mode. The MALDI-
TOF mass spectrum of spot 23 for 2001021K (Figure 3.3) showed a very low abundance 
peak that corresponded to peptide [194-216] (with one missed trypsin cleavage site). In 
most of the analyses, the signal observed for peptide [194-216] was weak; this fragment 





Figure 3.3 (following page) MALDI-TOF mass spectra of in-gel tryptic peptide 
mixtures of spots from tissue 2001021K (Figure 3.2[b]). Full sequence coverage for 
the LC was obtained in spot 23; amino acids not underlined were only observed in LC-
MS spectra. The terminal asparagine residue was deamidated in peptide [1-16] in spots 
23, 14 and 1.. The asparagine residue at position 174 was also mostly deamidated 
(peptide [171-190], [M + H]
+
 m/z 2316.115 in spot 23). All spots showed peaks that 
corresponded to the N-terminal peptide [1-16]; the methionine at 3
rd
 position was 
partially oxidized (+M(O)). Other sites of oxidation (+M(O) or +W(O)) and sodium 
adduction (+Na) are indicated by the labels on the spectra. The symbol “*” indicates 
tryptic peptides from serum amyloid P component (SAP), showing a co-localization of 












Compared to the full-length protein, LC fragments were located in a region of the 
gel that was more acidic; apparent molecular weights ranged from 10 to 20 kDa. Even 
when highly truncated, the LC fragments from four of the kidney samples had observable 
peaks for the tryptic peptide [1-16], the N-terminal region of the LCs (Figures 3.3-3.6), 
with sequences that were confirmed by LC-MS/MS analysis. The methionine residue at 
the third position in the amino acid sequences of all four samples was present in both 
oxidized and native forms. For the LC proteins found in spots 23, 14 and 1 of sample 
2001021K, the N-terminal asparagine residues were mostly deamidated. The asparagine 
residue at position 174 was also mostly deamidated (peptide [171-190], [M + H]
+
 m/z 
2316.115 in spot 23) in the full-length LC 2001021. The MALDI-TOF mass spectra for 
LC protein/fragments deposited in 2001021K (Figure 3.3) showed clearly that, as the 
molecular weight decreased, more of the constant region had been removed. For 
example, the peak for peptide [115-133] ([M + H]
+
 m/z 2043.039 in spot 23) was barely 
detectable in spot 5 and had disappeared from spot 12. For sample 2001021K, spots 14, 
1, 5, and 12 had sequence coverage of amino acids [1-175], [1-153], [1-133], and [1-114], 
respectively, showing a ladder of degradation. Sequence coverage for LC fragments in 
the other samples is listed in Figures 3.4-3.6. LC fragments from sample 2000075K had 
sequence coverage of [1-134] and [1-115], indicating the occurrence of truncation sites at 
the amino acid end residues prior to the next trypsin cleavage sites (lysine or arginine 
residue). The result was quite similar for tissue 2001095K. For 2005135K, LC fragments 
showed a pattern that displayed two trains of spots which had similar MALDI-TOF mass 




sites located between amino acids 135 and 154 that created fragments with molecular 
weights between approximately 14.4 and 16.6 kDa without allowance for other PTMs. 
No C-terminal truncations were observed. While the extent of amyloid fibril processing 
may be somewhat patient- and organ-specific, our data on LCs deposited in the kidney 
shows similar sequence coverage for part of their LC fragments and suggests that organ-
specific proteolysis events may take place. 
In summary, the sequence coverage of the four kidney tissue samples analyzed 
here indicated that the deposited LC fragments had intact N-termini and each retained, at 





Figure 3.4 MALDI-TOF mass spectra of in-gel digested tryptic peptide mixtures 
obtained for spots from tissue 2000075K (Figure 3.2[a]). Sequence coverage labeled in 





Figure 3.5 MALDI-TOF mass spectra of in-gel tryptic peptide mixtures obtained for 
spots from tissue 2001095K (Figure 3.2[c]). Sequence coverage labeled in the figure 
has been confirmed with LC-MS/MS analysis. Spot 2 had tryptic peptide peaks that 







Figure 3.6 MALDI-TOF mass spectra of in-gel tryptic peptide mixtures obtained for 
spots from tissue 2005135K (Figure 3.2[d]). Sequence coverage labeled in the figurehas 
been confirmed with LC-MS/MS analysis. These two spots showed similar MALDI mass 
spectra. This result was possibly due to the presence of two/multiple proteolysis sites 
between amino acids 135 and 154, creating fragments with molecular weights between 






3.3.2 Characterization of Circulating LCs in Serum Samples 
Serum samples were obtained from the same five patients whose kidney tissue-
deposited LCs had been analyzed. IFE indicated that serum 2005135S had IgA in 
circulation and there were no free LC proteins in serum 2001095S. The other three sera 
all had free LCs. 
After albumin-depletion, proteins from the five serum samples were subjected to 
2D SDS-PAGE separation, with 450 μg of proteins loaded onto each gel. Under reducing 
conditions, intact IgA or IgG should release the LCs. SDS-PAGE gels of serum samples, 
2001021S and 2005135S, are shown in Figure 3.7. Results from the remaining three sera 
are shown in Figure 3.8. In these samples, spots with molecular weights ≤ 25 kDa were 
cut and analyzed, as discussed previously. Actually, this part of the gel showed patterns 
that were similar among the five serum samples. 
In-gel tryptic digestion and further MS analysis demonstrated the presence of 
intact LCs in all five sera. Spot a for 2001021S, spots 1-3 for 2005135S (Figures 3.7 and 
3.9), and circled spots on the gels containing the proteins from the other three sera 







Figure 3.7 2D SDS-PAGE gels of albumin depleted serum samples [a] 2001021S and 
[b] 2005135S. For each gel, 450 μg of proteins were loaded. Spot a in [a] and spots 1-3 in 
[b] contained LC sequences. Assignments of other spots to associated proteins are 






Figure 3.8 2D SDS-PAGE gels of albumin depleted serum samples [a] 2000075S, [b] 
2003118S and 2001095S. For each gel, 450 μg of proteins were loaded. Circeled spots 







































































































































































































































































































Figure 3.10 MALDI-TOF mass spectra of in-gel tryptic peptide mixtures obtained 
for LC spots from serum samples 2000075S, 2003118S and 2001095S. Methionine 
residues in peptides [1-16] were partially oxidized in all three spots.  “+Na" and “+K”: 
sodium and potassium adducts, respectively; T: trypsin autolysis peak. 
 
Furthermore, groups of spots with molecular weights around 25 kDa showed a 
mixture of polyclonal LCs of both κ (mostly) and λ types, and also apolipoprotein A-I 
(APOAI). In the lower part of the gel, there appeared a group of spots with molecular 







well as a group of spots with molecular weights around 15 kDa in 2005135S (labeled as 
spots 4 and 5), 2000075S, 2003118S and 2001095S; these were identified as truncated 
forms of haptoglobin (MALDI mass spectrum of selected spots shown in Figure 3.11). 
The spot with molecular weight ~ 15 kDa was identified as TTR.  
 
Figure 3.11 MALDI-TOF mass spectra obtained for tryptic digests of spot b in 
2001021S (Figure 3.7 [a]) and spot 4 in 2005135S (Figure 3.7 [b]). Both were 
identified as haptoglobin fragments by LC-MS/MS analysis. Asparagine at the 5
th
 







It has been reported that truncated LC fragments have been found in the plasma of 
patients with AL amyloidosis 
(95, 96)
; this finding was interpreted as evidence of a LC 
synthesis defect. In the study presented here, no spots that corresponded to truncated 
species were observed in this study of AL sera using 450 µg of protein/sample. This 
result could be due to the presence of only low concentrations of circulating LC 
fragments, complete absence of LC fragments in sera, or the existence of LC fragment 
complexes containing other blood components. Coomassie staining usually has a 
detection limit of 0.2-5 ng. Considering the fact that full-length LCs were observed in all 
five sera, our data suggest that LC proteins are fragmented after amyloid deposition. 
The cDNA-deduced sequence of the LC protein 2005135 included the triplet 
194NYS, which predicted Asn194 as a glycosylation motif (N-X-T/S, where X≠P). Spots 
1, 2, and 3 in Figure 3.7 [b] showed similar MALDI-TOF mass spectra (Figure 3.9), 
although the former two had higher apparent molecular weights. Moreover, the peak for 
tryptic peptide [192-208] ([M + H]
+
 m/z 1962.863) was only present in the mass spectrum 
obtained for spot 3. It seemed highly possible that LC 2005135 was glycosylated at 
Asn194, but the glycosylated peptide [192-208], with a higher molecular weight, was 
more difficult to detect in the unseparated tryptic digest. PNGase F, an amidase that 
removes N-glycans from N-linked glycoproteins, was applied to the tryptic peptide 
mixture from spot 1. As expected, a peak with [M + H]
+
 m/z 1963.842 appeared after this 
treatment, consistent with the formation of aspartic acid upon release of the glycan 




modes, possibly due to low ionization efficiency of the species. For sample 2005135S, 
the circulating IgA had both glycosylated and non-glycosylated amyloidogenic LCs. 
 
 
Figure 3.12 The region in the MALDI-TOF mass spectra obtained for the tryptic 
digest of spot 3 and PNGase F-treated spot 1 of 2005135S (see Figure 3.7 [b] for 
labeling of the spots). PNGase F removes the N-glycan attached to an asparagine residue 










Free circulating LCs were also pulled down from 40 μL of 2001021S and 
2000075S, using direct immunoprecipitation 
(251)
 with a polyclonal antibody against free 
λLC. The immunoprecipitated LCs were separated by 2D PAGE gels as shown in Figure 
3.13. Both sera were found to contain full-length LC proteins. Of note, LC spot a in 
Figure 3.7 [a] and spot a Figure 3.13 [a], and LC spot in Figure 3.8 [a] and spot 2 in 
Figure 3.13 [b], all appeared at similar gel positions. The MALDI-TOF mass spectra of 
the tryptic digests of the two immunoprecipitated LC spots are shown in Figure 3.14; no 
differences in spectra, as shown in the upper panels of Figs. 3.9 and 3.10, were observed. 
Spots 2-4 of Fig. 3.13 were also analyzed. Interestingly, these LC proteins have 
theoretical pI values that are heterogeneous suggesting the presence of modifications. 
However, no such PTMs have been identified. 
 
 
Figure 3.13 2D SDS-PAGE gels of free LCs immunoprecipitated from 40 μL of [a] 






Figure 3.14 MALDI-TOF mass spectra of tryptic digests of [a] spot a and [b] spot 2 
in Figure 3.13. “+Na”: sodium adducts; T: trypsin autolysis peak. 
 
3.3.3 Characterization of Urinary LCs 
Urine samples were also available from patients 2001021 and 2003118, and data 
from IFE indicated the presence of free LC proteins. Urine samples were dialyzed against 
water in dialysis tubing with a MWCO of 6-8 kDa. Both samples showed a relatively 
high concentration of albumin on 2D SDS-PAGE gels (Figure 3.15). Again, MS analysis 
confirmed the presence of LC proteins in both urine samples, labeled as spots 1-4 in 
Figure 3.15. The groups of spots (in the dashed square) besides spots 1 and 2 in the gel 










Figure 3.15 The 2D SDS-PAGE gels of urine samples 2001021U [a] and 2003118U 
[b]. Both samples showed a high content of albumin. Spots 1 to 4 in 2001021U and 
2003118U were determined to as correspond to the amylodigogenic LC proteins. Group 
of spots in the dashed square beside spots 1 and 2 in [a] were identified as degradation 






Sample 2001021U had LC spots (spots 1 to 4) that exhibited a decrease in 
apparent molecular weight, with the first two being located very close to one another on 
the gel. Examination of the tandem MS data for spot 1 confirmed that it was a full-length 
LC protein. Figure 3.16 shows the MALDI-TOF mass spectra recorded for these four 
spots. The peak corresponding to the methionine-oxidized tryptic peptide [1-16] ([M + 
H]
+
 m/z 1774.853), quite abundant in the mass spectrum of spot 1, had only low 
abundance in the mass spectrum of spot 2 and was missing from the mass spectra of spots 
3 and 4. Peaks with m/z 1775.849±0.003 in spots 2 to 4 were confirmed to be the peptide 
[176-190] with a di-oxidized tryptophan residue (accompanied by partial to full 
deamidation in some cases). The relative signal intensity for the peak corresponding to 
tryptic peptide [4-16] was increased in spot 2 compared to spot 1. Furthermore, the mass 
spectrum of spot 3 had a peak corresponding to peptide [37-62], whereas the mass 
spectrum of spot 4 included a peak with a mass assignment indicating modification of the 
peptide [39-62] by N-terminal pyroglutamate. Both assignments were confirmed by LC-
MS/MS analysis (Figure 3.17 shows tandem spectrum recorded for peptide [37-62]). 
Also, as determined by LC-MS/MS analysis, all four spots had intact C-termini. The 
reduced and alkylated derivatives of the protein, remaining after removal of the first 36 or 
38 amino acids, were expected to have molecular weights of 19.6 kDa and 19.3 kDa, 
respectively, and these values were consistent with the apparent molecular weights shown 
on the gel. The LCs in urine sample 2001021U were also found to be truncated with 





Figure 3.16 (following page) MALDI-TOF mass spectra of in-gel digested tryptic 
peptide mixtures of spots from the SDS-PAGE separation of the proteins in urine 
2001021U. Spots are numbered as in Figure 3.15. [a] Full mass range spectra. In spot 2, 
there was low abundance peak corresponding to peptide [1-16] with an oxidized 
methionine residue; this signal was not present in the mass spectra obtained for the 
digests from spots 3 and 4. Relatively high abundance signals corresponded to peptides 
[4-16] in spot 2, [37-62] in spot 3 and [39-62] (pyroglutamate formed at N-terminus) in 
spot 4. [b]. Peaks with m/z 1775.849 ± 0.003 in spots 2 to 4 could be assigned to the 



















Figure 3.17 Tandem MS spectrum of precursor ion [M + 4H]
4+
 m/z 744.1258 
measured in the LTQ-Orbitrap with HCD activation. Manual inspection of the data 
revealed the sequence for peptide [37-62] of amyloidogenic LC 2001021. 
 
Similar results were obtained from analysis of sample 2003118U spots 1 and 2 
(Figure 3.18). Thus, from the data obtained for the two urine samples studied here, it was 
evident that urinary LC proteins were also processed, but truncation in these samples took 
place at the N-terminus. The protein α-1 antitrypsin, also present in the urine samples, has 






been established whether this protease is also responsible for the presence of C-terminal 
LC fragments in urine. 
 
 
Figure 3.18 MALDI-TOF mass spectra of in-gel digested tryptic peptide mixtures 
from urine 2003118U. Spots are numbered as in Figure 3.15. N-terminal asparagine in 








LC 2005135 had a replacement of arginine with asparagine (Asn194) in the CL 
region and the serum LC was determined to be partially N-glycosylated in its circulating 
form. Glycosylation of both κ and λ types of Ig LCs has been reported, especially in the 
VL region 
(58, 82)
; furthermore, a higher frequency of glycosylation in amyloidogenic LCs 
compare to non-amyloidogenic LCs has been reported 
(55)
. In the case examined here, 
glycosylation in the CL region may change the charge distribution on the protein surface 
and influence the propensity for forming LC aggregates. Only N-terminal fragments, i.e. 
no full-length LCs, were found in kidney tissue deposits of 2005135K; truncations 
removed the N-glycosylation sites.  
Other detected modifications included oxidation (of methionine and tryptophan 
residues) and deamidation (of an asparagine residue). For LC 2001021, Asn1 and Asn174 
of the full-length protein were deamidated in spot 23 of the kidney autopsy, but no 
deamidation was observed elsewhere. It has been reported that even low levels of 
asparagine deamidation may contribute to the formation of amyloid aggregates 
(260)
. No 
other differences in PTMs were found in the LC proteins recovered from different 
sources in the same patient. 
 
3.4 Conclusions 
In summary, the characterization of IGLV6 LC proteins found in kidney autopsy, 
serum, and urine samples obtained from five patients strongly supported the hypothesis 
that the proteolytic processing of amyloidogenic LCs occurs after deposition in the organ. 




only full-length LCs were found in the serum samples. Mostly N-terminal LC fragments, 
together with a very small amount of full-length (in 2001021K only) LCs were found 
deposited in the kidney tissues. Similar sequence coverages could be seen for the N-
terminal truncations among different patients. C-terminal LC fragments, found in the two 
urine samples studied, were not present in the deposited forms. More research should be 











As a form of systemic amyloidosis, AL can afflict multiple vital organs in the 
body including the heart, kidney, and liver. Cardiovascular complications are especially 
common for AL and heart failure can be a primary cause of death in this disease. There is 
evidence that, with increased cellular oxidative stress, amyloidogenic Ig LC proteins can 
compromise cardiomyocyte functions 
(261, 262)
. Infusion of isolated mouse hearts with 
LCs, isolated from the urine of patients with AL cardiac amyloidosis, can cause oxidative 
stress 
(263)
. Upon exposure to amyloidogenic LCs, human coronary artery endothelial 
cells can develop responses and injuries characteristic of oxidative stress 
(264)
. Increased 
oxidative stress may also be responsible for multi-organ dysfunction in AL. Compared to 




Oxidative stress is usually associated with a burst of reactive oxygen species 
(ROS). Excess ROS can cause damage to almost all biomolecules with important 
physiological functions, including proteins, lipids and DNA, and they are now believed to 






There are multiple sources for ROS, both exogenous and endogenous 
(265)
. 
Ultraviolet light and environmental toxins play important roles as exogenous factors. In 
vivo, neutrophils are a major source for ROS. Under stimulated (inflammation) 
conditions, neutrophils can not only generate hydrogen peroxide (H2O2), but also release 
a heme peroxidase enzyme called myeloperoxidase (MPO) 
(268-270)
. The latter, under 
physiological conditions, can convert H2O2 and chloride (Cl
-
) into hypochlorous acid 
(HOCl). HOCl is a strong oxidizing and chlorinating agent that reacts with many 
functional groups. Neutrophil/MPO is a key element of our defense system, e.g. killing of 
bacteria. However, it can also cause problems to the host. Oxidation of low-density 
lipoprotein (LDL) by MPO, turns LDL into a form more likely to be taken up by 
macrophages resulting in a higher risk for cardiovascular diseases 
(271)
. In cases of renal 
failure, infiltration of neutrophils aggravates the situation by destroying normal cells and 
tissues with oxidizing agents 
(272, 273)
. Thus, it is important to find proper markers of 
elevated HOCl in order to facilitate assessment and treatment of these and other 
conditions. 
For peptides and proteins, HOCl reacts with both the peptide bonds and the amino 
acid side chains. Reactions with peptide bonds can ultimately lead to fragmentation and 
degradation of peptides and proteins. Among the amino acids, HOCl reacts fastest with 
residues containing sulfur in their side chains, namely cysteine and methionine 
(274)
. It can 
also react with the side chains of some other amino acids, including tyrosine and lysine, 
and with free N-terminal α-amino groups (274, 275). Chlorination of the aromatic ring of the 






laboratory has previously detected monochlorinated tyrosine residues in amyloidogenic 
κLC proteins (60). Di-chlorination of tyrosine in vivo has not been reported, perhaps 
because these modified residues are usually present at very low concentrations. HOCl 
also reacts readily with amine groups, such as those present on the lysine side chain or a 




In the research reported in this chapter, we studied the amyloidogenic LC proteins 
purified from urine and serum samples obtained on a patient with AL amyloidosis. 
During the analysis, it became apparent that this patient experienced significant oxidative 
stress, since the LC protein was found to be heavily modified at tyrosine and lysine 
residues. Some of the tyrosine residues in the proteins were mono- and/or di-chlorinated. 
The side chains of some lysine residues were converted to nitrile groups. In vitro studies 
with the MPO-H2O2-Cl
-
 system and model peptides showed the same types of oxidative 
modifications. 
 
4.2 Methods and Experiments 
Urinary LC protein from a patient with AL amyloidosis was purified and 
characterized extensively, using both in-solution and in-gel digestions with different 
proteases, followed by MS analysis. LC proteins were immunoprecipitated from serum 
(as described in Chapter 2) and assayed for comparison purposes. In vitro oxidation of 
synthetic peptides was carried out with the MPO-H2O2-Cl
-




The mixture was fractionated with HPLC separation. Chemical tests and MS analyses 
were performed to characterize the products in the fractions. 
 
4.2.1 De-identified Patient Profile 
AL01-068 was a Hispanic woman, 65 years old at her initial visit to our clinic.  
Primary and secondary organ involvements were renal and cardiac, respectively.  
However, she also had gastrointestinal and soft tissue involvement. She had 10-15% 
plasma cells in her bone marrow, and these were found to be lambda predominant. Her 
disease was very aggressive, with time from first symptom to death of ~1 year. (She 
passed away 2 months after she was seen at our clinic.) The amyloid load, as estimated 
by CR staining, was 2+ in a kidney biopsy and 1+ in an abdominal fat aspirate. The 
clonal LC sequence was deduced from bone marrow cDNA and found to be λ2 subclass 
from VL germline gene 2b2. Data courtesy of Amyloid research laboratory of Boston 
University.  
 
4.2.2 LC Protein Purification and Analysis 
Protein purification of the LC in a urine sample from the patient was carried out 
according to a protocol that was well-established in our laboratory and reported 
elsewhere, with minor modifications 
(60)
. In brief, the urine sample was dialyzed against 
deionized H2O in dialysis membrane tubing (Spectrum Laboratories) with MWCO 12-
14,000 Da through three separate changes. The dialyzed sample was then lyophilized and 
stored at -20 
o




and passed through four Hi-Trap Blue columns (GE Healthcare Bio-Sciences) to remove 
albumin. The albumin-depleted sample was again dialyzed in dialysis membrane tubing 
with MWCO 6-8,000 Da and lyophilized. Further purification was performed with a 
Sephacryl S-200 (GE Healthcare Bio-Sciences) size exclusion column (3 x 80 cm) in 
PBS buffer at room temperature using a flow rate of 2 mL/min. Fractions were collected, 
dialyzed, and lyophilized. Lyophilized samples were checked with SDS-PAGE and 
Western blot to detect the presence of LC proteins. 
The serum sample was collected at the same clinical visit as the urine sample 
described in the preceding paragraph. The LC protein was immunoprecipitated from 
serum using the direct IP method described in Chapter 2. 
 For in-solution protein digestion, the lyophilized LC protein was initially 
reconstituted in 50 mM ABC buffer at a final concentration of 0.5-1 μg/μL. The protein 
solution was then incubated with 5 mM DTT at 55 
o
C for 1 hr. After the mixture was 
cooled to room temperature, alkylation was carried out using iodoacetamide at a 
concentration of 10 mM. The reaction took place in the dark at room temperature for 0.5 
hr. To quench the excess of iodoacetamide, more DTT was added to reach a final 
concentration of 20 mM. Protein digestions were carried out with the protease at a weight 
ratio of 1:50 (protease: protein) and incubated overnight at 37 
o
C. The next day, protein 
digests were dried on a SpeedVac for future use. 
Ig LC AL01-068 was also further purified by SDS-PAGE, using a 4-12% gradient 
gel. To obtain the monomer, the band with an apparent molecular weight just over 25 




4.2.3 Peptide Oxidation Preparation and HPLC Separation 
Synthetic peptides were produced and purified by GenScript with three different 
sequences: peptide A - VLIYEDFKR; peptide B - VLIYEDFRR; peptide C - 
VLIFEDFKR. All three peptides were acetylated at the N-terminus and amidated at the C 
–terminus; the peptides exhibited greater than 98% purity. 
For oxidation, 10 nmol of synthetic peptide was dissolved in 20 μL PBS buffer, 
and 0-2 pmol MPO and 0-20 nmol H2O2 were added sequentially. The H2O2 was added to 
the mixture in several aliquots at intervals of 3-5 min while the mixture was shaken 
thoroughly and incubated at 37 
o
C before dried on a SpeedVac for downstream 
applications. For a larger scale reaction, NaClO (molar ratio, peptide: NaClO = 1:40) was 






The peptide reaction products from treatment with MPO-H2O2-Cl
-
 were purified 
with a C18 ZipTip
®
, lyophilized, reconstituted in buffer A (1% ACN/99% H2O/0.1% 
TFA), and loaded onto an Agilent HPLC (1200 series, Aligent Technologies) equipped 
with a Vydac
®
 C18 column (5 µm particle size, 2.1 mm x 250 mm) (Grace
 
Davison 
Discovery Sciences). Buffer B was made of 99% ACN/1% H2O/0.1% TFA. The flow rate 
was kept constant at 0.2 mL/min. Separation was achieved with a gradient elution: 0-2 
min, 1-3% buffer B; 2-40 min, 3-70% buffer B; 43-46 min, 70-90% buffer B; 46-49 min, 
90-3% buffer B.  
The reaction products from treatment of each synthetic peptide with NaClO were 




larger quantity. The reaction mixtures were desalted with Sep-Pak C18 cartridges 
(Waters) before being lyophilized. The C18 column was Adsorbosphere HS (7 µm 
particle size, 10 mm x 250 mm) from Alltech Associates. The flow rate was 3.5 mL/min. 
The elution gradient was as follows: 0-7 min, 1-3% buffer B; 7-22 min, 3-40% buffer B; 
22-45 min, 40-70% buffer B; 45-48 min, 70-90% buffer B; 48-51 min, 90-90% buffer B; 
51-55 min, 90-3% buffer B.  
Both columns were used at room temperature with detection of peptides at 214 
nm. Fractions were collected manually. 
 
4.2.4 2, 4- Dinitrophenylhydrazine Test for Aldehyde Group 
A methanol solution saturated with 2,4-dinitrophenylhydrazine (DNPH) was 
freshly prepared. The supernatant was then diluted with a 1:1 ratio of ultrapure water. 
Ten microliters of this solution were added to each dried HPLC fraction, followed by 
addition of 0.2 µL HCl (12 N). The mixture was incubated at room temperature for 1 hr 
before it was taken to dryness on a SpeedVac and stored for future analysis. 
 
4.2.5 Click Chemistry Test for Nitrile Group 
Click chemistry between a nitrile group and NaN3 was performed according to 
published protocols 
(281, 282)
 with modifications for a small-scale reaction. Each dried 
HPLC fraction was resuspended in 120 µL water and 2-propanol (volume ratio, 2:1) 
solution. The solution was transferred to a glass reaction vial before adding NaN3 and 




peptide. The mixture was incubated at 80 
o
C for 24 hr. Finally, 0.2 µL 12N HCl was 
added to the mixture, which was then dried on a SpeedVac and stored until further 
analysis. 
MALDI-TOF mass spectra were recorded with an ultrafleXtreme™ MALDI-
TOF/TOF MS, if not specified otherwise (Bruker Daltonics). Tandem MS analysis used 
to confirm sequence or deduce modification information was performed with different 
instruments, as noted below. An ESI ion trap instrument, the amaZon™ ETD (Bruker 
Daltonics), was used with CID activation. The sample, at a concentration of 0.7 pmol/μL, 
was directly infused at a flow rate of 2 μL/min. LC-MS/MS was performed with an LTQ-
Orbitrap XL™ MS (Thermo Fisher Scientific) coupled to both a nanoACQUITY UPLC® 
system (Waters) and an Advion TriVersa NanoMate™ system (Advion Biosciences) with 
HCD activation. Tandem MS data were analyzed using Proteome Discoverer 3.0 
(Thermo Fisher Scientific) with SEQUEST search against the protein sequence of Ig LC 
AL01-068. Search parameters were same as those detailed in Chapter 2. 
Tandem MS analysis of the synthetic peptide samples, including the HPLC 
fractions and reaction products, was carried out on a solariX™ 12-T FT MS (Bruker 
Daltonics) with CID excitation. The sample was sprayed with a nanoESI source at the 








4.3 Results and Discussion 
4.3.1 Post-translational Modifications of Urinary LC AL01-068 
Tryptic peptides obtained by in-solution digestion of Ig LC AL01-068 were first 
checked with a MALDI-TOF MS instrument (Figure 4.1). Ten micrograms of Ig LC 
AL01-068 was further purified with a reducing SDS-PAGE gel (Figure 4.2). Monomer, 
dimer and higher aggregated forms of this LC protein appeared. The band for the LC 
monomer was sliced for in-gel protease digestion. 
In-solution digestions with other proteases, including GluC and LysC, were also 
performed. Full sequence coverage of the protein was achieved, by combining data from 
various characterization methods (Figure 4.3). No conflicts with the cDNA-deduced 
sequence were found.  
A peptide with [M + H]
+
 m/z 4889.341 could be assigned to a modified N-
terminal peptide (1-47), observed in the MALDI-TOF mass spectrum and also detected in 
the LTQ-Orbitrap
TM
. However, HCD excitation yielded just a few fragment ions. The 
data indicated that the N-terminal glutamine had been converted to pyroglutamate, and 
this PTM was confirmed by a tandem mass spectrum obtained with CID activation in the 
amaZon
TM
 ion trap instrument (Figure 4.4). The conversion to pyroglutamate can happen 








































































































































































































































Figure 4.2 SDS-PAGE gel of 10 µg AL01-068. Coomassie staining showed several 
bands for different proteoforms. The arrow points to the band corresponding to the 







Figure 4.3 Sequence coverage of Ig LC AL01-068 with various characterization 
methods. For a, b, and c, the reduced and alkylated Ig LC AL01-068 was in-solution 
digested with GluC, LysC and trypsin respectively. For d, Ig LC AL01-068 was in-gel 
digested with trypsin. The peptide mixture derived by method c was sequenced on the 
amaZon
TM
 with CID activation. All other mixtures were characterized by ESI-LC-
MS/MS with HCD fragmentation on the LTQ- Orbitrap
TM
. 
  1 QSALTQPASV SESPGQSITI SCTGSSSNIG SNNFVSWYQH IPGEAPKVLI 50 
a 
b                                                      ___ 
c   ______________________________________________________ 
d                                                      ___ 
                                                     
 51 YEDFKRPSEI SDRFSGSKSG NTASLTISGL RPEDEGDYYC CSKTVTDTLL 100 
a     ____________________________________________________ 
b   ______________________________________________________ 
c   ______________________________________________________ 
d   ______________________________________________________ 
 
101 FGGGTKLTVL RQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150 
a   ______________________________________________________ 
b   ____________________________________ 
c   ____________________________________ 
d   ______________________________________________________ 
 
151 AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHKTYSCQVT 200 
a   _______________                         ______________ 
b      ___________________________________________________ 
c      __________________                       __________ 
d   ______________________________________________________ 
 
201 HEGSTVEKTV APTECS 216 
a   _________________ 
b   _________________ 
c   _________________ 




















































































































The tryptic digest of Ig LC AL01-068 showed peptides with mass differences of 
34 Da or 68 Da, which had the same isotopic distributions as were observed for the 
mono-/di- chlorinated synthetic peptides; all were consistent with theoretical 
distributions. Figure 4.5 [a] shows an example of the MALDI-TOF peaks of the [M + H]
+
 
signals assigned to the peptide [48-63] (enlarged from Figure 4.1). Further analysis with 
LC-MS/MS on the LTQ-Orbitrap
TM
 instrument proved that there was a chlorine 
substitution on tyrosine 51 (Figure 4.5 [b]). Dichlorination was also detected as a 
modification on tyrosine 51 and this was confirmed by the MS/MS data (Figure 4.5 [c]). 
For Ig LC AL01-068, a total of three tyrosine residues were found to be partially 
chlorinated, including tyrosines 51, 176, and 195 (Figures 4.6, and 4.10). Among these, 
tyrosines 51 and 176 were found in both mono- and di- chlorinated forms. The peptide 
with monochlorinated tyrosine 195 was observed in the LC-MS analysis, but was not 
observed with the MALDI-TOF MS instrument. This inconsistency may be due to the 





Figure 4.5 (following page) Tyrosine 51 of Ig LC AL01-068 was partially 
monochlorinated and partially dichlorinated. [a]  Expansion of a selected region of the 
mass spectrum shown in Figure 4.1. Tandem MS spectra [b] for the monochlorinated 
peptide [48-55], [M + 2H]
2+
 m/z 520.7870, and [c] for the dichlorinated peptide [48-63], 
[M + 4H]
4+
 m/z 509.9923. The in-gel tryptic digest of the Ig LC AL01-068 monomer was 











Figure 4.6 Tyrosines 176 [a, b] and 195 [c] were chlorinated. ESI-HCD-MS/MS was 
performed [a] for the monochlorinated peptide [176-190], [M + 2H]
2+
 m/z 889.4139; [b] 
for the dichlorinated peptide [176-193], [M + 2H]
2+
 m/z 1080.9742 and [c] for the 
monochlorinated peptide [194-208] [M + 2H]
2+
 m/z 800.3716. The chlorinated peptide 
[176-193] also showed a 4 Da loss on lysine 190. The cysteine residue in peptide [194-





Tandem MS spectra with HCD fragmentation and detection in the Orbitrap
TM
 
showed a molecular weight loss of 4.0300 Da for tryptic peptide [154-170] ([M + 2H]
2+
 
m/z 837.9309) (Figure 4.7). According to the tandem MS spectrum, the modification 
occurred at the residue Lys160. More modifications at lysine residues with a molecular 
weight loss of 4 Da were observed in the LC-MS/MS including lysines 55, 106, 114, 160, 
170, 175, 190, 193, and 208 (see Figures 4.6 and 4.8 for modifications on lysines 106, 
190 and 208).  
 
 
Figure 4.7 Lysine 160 of Ig LC AL01-068 was modified. ESI-HCD-MS/MS ([M + 
2H]
2+
 m/z 835.9159) showed it had a molecular weight loss of 4.0300 Da and the 









Figure 4.8 Lysine residues 106 and 208 of Ig LC AL01-068 were modified. ESI-HCD-
MS/MS was performed [a] for modified peptide [194-111], [M + 2H]
2+
 m/z 944.5308; [b] 
for modified peptide [194-216], [M + 2H]
2+ 
m/z 1284.0560; and [c] for differently 
modified peptide [194-216] [M + 2H]
2+
 m/z 1285.5538. Cysteine residues 197 and 215 





Modified lysine resides were no longer recognized by trypsin thus leading to 
generation of mis-cleaved peptides. For in-solution trypsin digestion, the relative 
intensity for the signal corresponding to peptide [94-111], which had the Lys106 residue, 
dramatically decreased; this is shown by the MALDI-TOF mass spectrum recorded after 
24 hr of incubation (Figure 4.9). However, the peptide with the modified lysine residue 
([M + H]
+
 m/z 1888.02) remained intact. The MALDI-TOF mass spectrum was recorded 
on a Reflex IV™ MS (Bruker Daltonics). 
 
Figure 4.9 MALDI-TOF mass spectra of two peaks. Relative intensities of in-solution 
tryptic peptides [94-111] with ([M + H]
+
 m/z 1888.02) and without ([M + H]
+
 m/z 
1892.05) a modified lysine residue after 4, 8 and 24 hr of incubation, respectively, were 
shown. 
 
Some other oxidative modifications were also observed. For example, tryptophan 






modified (Figures 4.1 and 4.11). In addition to providing evidence for the possible side 
products from reduction and alkylation, the mass spectrum in Figure 4.11 indicated the 
presence of a possible product from oxidation at cysteine 90 (didehydro); the MS peak 
for this feature was also shown in Figure 4.1. It remains unclear whether these 
modifications are artifacts or not. 
Digestions of non-reduced and alkylated LC AL01-068 proteins were also 
analyzed. No further PTMs were found. 
 
 
Figure 4.10 Tryptophan 189 of Ig LC AL01-068 was oxidized. ESI-HCD-MS/MS was 
performed for modified tryptic peptide [176-190], [M + 2H]
2+
 m/z 897.4114 . Tyr176 in 







Figure 4.11 Cysteine 90 of Ig LC AL01-068 was modified to didehydro-cysteine. ESI-
HCD-MS/MS was performed for modified peptide [69-93], [M + 3H]
3+
 m/z 907.7326. 
The other cysteine was carbamidomethylated. 
 
4.3.2 In vitro Tyrosine Chlorination Study 
Tyrosine residues can be chlorinated by HOCl (Figure 4.12 [a]). MPO is a human 
enzyme, released by stimulated neutrophils. As a peroxidase, it can oxidize peroxidase 
substrates which results in the formation of radical intermediates. The MPO-H2O2 system 
plays an important role leading to the formation of ROS, including the conversion of 
chloride ions into the powerful oxidant HOCl (Figure 4.12 [b]). It is highly possible that 









Figure 4.12 Reactions involved in peptidyl tyrosine chlorination. [a] The tyrosine 
residue can be monochlorinated or dichlorinated by HOCl. [b] Production of HOCl from 
H2O2 and Cl
-
 with MPO catalysis.  
 
 Synthetic peptide A has the same amino acid sequence as Ig LC AL01-068 
peptide [48-56], VLIYEDFKR, with both terminals modified (theoretic [M + H]
+
 m/z 
1223.6783). The free amine at the N-terminus, which otherwise would react with HOCl, 
was acetylated. In vitro incubation of this peptide with MPO and H2O2 in PBS buffer led 
to formation of mono-/di- chlorination products (observed [M + H]
+
 at m/z 1257.66 and 







Figure 4.13 Molecular ion regions in the MALDI-TOF mass spectra of the treated 
synthetic peptides A and B. (top and middle panels) Incubation of peptide A ([M + H]
+
 
m/z 1223.70) with MPO-H2O2-Cl
-
 system but not H2O2 alone gave chlorinated species. 
(lowest panel) Incubation of peptide B with MPO-H2O2-Cl
-
 system ([M + H]
+
 m/z 
1251.71) (peptide A contains a Lysine residue but peptide B has no lysine) also led to 
chlorination modifications. “+Na”: sodiated peptide peak. 
 
The CID MS/MS spectrum recorded with the solariX
TM
 FT-MS identified the 
monoclorinated species as sole tyrosine monochlorinated product (Figure 4.14) of the 
reaction. However, close examination of the dichlorinated species revealed multiple 
possibilities (Figure 4.14).  Figure 4.14 compares the tandem FT-MS spectra of 
precursors [a] [M + 2H]
2+
 m/z 629.32±2 (monochlorinated) and [b] [M + 2H]
 2+
 m/z 
646.30±2 (dichlorinated). While the un-shifted y5 was only detected in [a], peaks that 
exhibited shifts of 34 (y5
*
) and 68 (y5
**
) Da were detected in [b]. These data indicate that 





[b], considering the shifted (b6
*
, shifted 34) and un-shifted (b6) peaks for b6,
 
the tyrosine 
residue could be unmodified or monochlorinated. The two added chlorine atoms in [b] 
(the species with [M + H]
+
 m/z 1291.62 in Figure 4.13) could be modified solely at the 
lysine side chain (to yield chloramines); likewise one chlorine may be present both on the 
lysine and tyrosine residues. It should be noted that the lysine side chain, as a primary 
amine, will react with HOCl to form a chloramine (RNHCl, RNCl2). Under physiological 
conditions, although the reaction rate constant for chloramine formation is lower than that 
for a free N-terminal amine, it is still higher than the rate constant for chlorination of the 






Figure 4.14 ESI-CID-MS/MS of the chlorinated species generated from incubation 
of peptide A with MPO-H2O2-Cl
-
 system. The precursor ions selected were [a] [M + 
2H]
2+
 m/z 629.32±2 and [b] [M + 2H]
 2+
 m/z 646.30±2. The peptides that correspond to 
peaks labeled with “*” contain one chlorine atom, and those with “**” contain two 
chlorine atoms. On the basis of these mass spectra, we could determine that, in [a], the 
one chlorine atom was located on the tyrosine residue; in [b] the two added chlorine 
atoms could both been substituted on the lysine side chain (chloramines) or one could 







To avoid interference from the lysine side chain, synthetic peptide B was 
constructed with replacement of the lysine by arginine (theoretical [M + H]
+
 m/z 
1251.6844); this modification would still contribute to a positive charge but the side 
chain would be less reactive with HOCl. Using the same reaction conditions as for 
peptide A, treatment of peptide B with MPO and H2O2 yielded fewer chlorinated species 
(Figure 4.13). 
The mechanism for tyrosine aromatic ring chlorination is still not clear. Kettle et 
al. proposed that, rather  than direct chlorination of the aromatic ring, chloride atoms 
were actually rearranged from an initially formed chloramine to a tyrosyl residue
(276)
,. 
They suggested that the nearby lysine residue might accelerate the tyrosine chlorination 
reaction. For the Ig LC AL01-068, a total of three tyrosine residues were found to be 
partially chlorinated, including tyrosines 51, 176, and 195 which were three, zero, and 
one amino acid (s) distant from a lysine residue, respectively. However, tyrosines 88 and 
89, which immediately precede cysteine residues, were not chlorinated, perhaps due to 
steric hindrance. However, we did not observe that any chlorinated lysine residues were 
chlorinated in Ig LC AL01-068, although chlorine atoms could have been transferred to a 
tyrosine residue. Some other mechanism may be responsible for the in vivo action of 
HOCl. 
 
4.3.3 In vitro Lysine Oxidation Study 
Synthetic peptide A was reacted with HOCl; this treatment also gave rise to an [M 
+ H]
+




molecular weight was 4 Da less than the neighboring unmodified peptide peak (Figure 
4.13). We then proposed that the MPO-H2O2-Cl
-
 system was responsible for this type of 
modification at lysine residues. Synthetic peptide C, which had a phenylalanine residue 
instead of tyrosine when compared to peptide A (theoretical [M + H]
+
 m/z 1207.6834), 
was also incubated with the MPO-H2O2-Cl
-
 system (Figure 4.15). For this peptide, the 
peak with a 4 Da mass shift was also observed. The reaction products were separated on a 
C18 column and three well-resolved peaks were eluted (Figure 4.16 [a]). MALDI-TOF 
mass spectra showed an efficient separation of the three species (Figure 4.16 [b]). On the 
basis of these observed mass differences, we postulated that products b and c had an 




Figure 4.15 MALDI-TOF mass spectra for treated synthetic peptide C. Incubation of 
peptide C ([M + H]
+
 m/z 1207.65) with MPO-H2O2-Cl
-
 system, but not H2O2 alone, gave 









Figure 4.16 Separation of peptide mixture generated in Figure 4.15. The separation 
on an Agilent HPLC equipped with a Vydac
R
 C18 column (5 µm particle size, 4.6 mm x 
250 mm) gave three peaks (A). A scale expansion of the window containing the products 
is also shown. (B) MALDI-TOF mass spectra recorded for these three species revealed a 
as the unmodified peptide, b as the reaction product with 1 Da loss and c as the product 










Figure 4.17 Oxidation of peptidyl lysine. HOCl treatment can oxidize the lysyl residue 
to to [a] allysine or [b] a product with a nitrile group.  
 
 To explore this hypothesis, a 5 mg sample of synthetic peptide C was incubated in 
a large excess of NaOCl at pH 7.4. Under these conditions, NaOCl exists as a mixture of 
HOCl and OCl
-
, making it an inexpensive substitute for MPO-H2O2-Cl
-
. The product 
mixture was separated on a semi-preparative C18 column and yielded the same fractions 
of a, b and c. In this way, relatively large amounts of the products were prepared and 
purified in a more cost efficient manner. 
 DNPH is a chemical which is widely used to detect the presence of a carbonyl 
group as a ketone or an aldehyde. If enough material reacts with DNPH, a positive result 
will be indicated by the formation of an observable precipitation. Here, the reaction of 
fraction b with DNPH showed the formation of a component that displayed a 180 Da-
mass shift with respect to the starting material (Figure 4.18). The unmodified peptide 






side chain (formation of allysine). This type of lysine oxidation product had also been 
detected in Ig LC AL01-068 (Figure 4.8 [c]). It should also be noted that the reaction of 
fraction b with DNPH also yielded [M + H]
+
 peaks at m/z 1203.70 and 1207.72. These 
results suggest that fraction b was not stable and underwent further reaction or was 
converted back to the starting material. 
 
 
Figure 4.18 Identification of fraction b. MALDI-TOF mass spectrum of the product 
mixture from fraction b upon reaction with DNPH showed a peak with a mass shift of 
180 Da. Peak labeled with “*” was a side product with a nitroso group. The control 










“Click chemistry” was employed to investigate the presence of a nitrile group, 
where it would be expected to react with an azide functional group to produce a ring-
containing species due to cycloaddition. Fraction c was treated to “click” with NaN3 in 
catalysis of ZnBr under 80 
o
C for 24 hr (Figure 4.19). The desired product with a 43-Da 
mass increase was detected. This result confirmed that HOCl treatment could produce a 
nitrile group via lysine side chain oxidation. The reaction led to partial conversion back 
to unmodified peptide C just like in Figure 4.18. 
 
Figure 4.19 Identification of fraction c. MALDI-TOF mass spectrum of product 
mixture of fraction c “clicked” with NaN3 shows a peak with a 43-Da mass shift. Fraction 
c was incubated with NaN3 and ZnBr2 in water and 2-propanol solution (volume ratio 
2:1) at 80 
o
C for 24 hr. The control reaction of fraction a with NaN3 gave no products. 






 The lysine residue, with a primary amine-containing side chain, is chemically 
very active. In vivo, it can be oxidized to 2-aminoadipic acid and allysine. The latter can 
be also produced by lysyl oxidase in the extracellular matrix. Oxidation of LDL with 
HOCl can cause lysine oxidation and subsequent protein aggregation 
(271)
. Lysine 
monochloramine, an oxidative product from HOCl, is a transient intermediate that reacts 
more rapidly with HOCl than lysine and is converted into dichloramine. It seemed 
possible that, because of excess of HOCl, chlorinated lysine residues were further 
decomposed into carbonyls and nitriles in the current study. Stelmaszynska and 
Zgliczynski reported that the final products of dipeptide chlorination mediated by HOCl 
were N-(2-oxoacyl) amino acids and nitriles 
(286)
. However, the chloramines were formed 
at the N-terminal amino group, and the nitriles were released when the dichloramines 
were decomposed with HCl. The nitrile bond was formed between the N-terminal 
nitrogen atom and the connecting carbon atom. Lysosphingolipids treated with HOCl can 
also produce nitriles 
(287)
. However, oxidation of the side chain of lysine residues in 
proteins to form nitrile structures has not been reported. So far as we can determine, ours 
is the first report of nitrile formation in vivo. The monochlorinated tyrosine residue has 
been used as a biomarker for the presence of HOCl. Di-chlorination of tyrosine residues 
and formation of a nitrile group from a lysine side chain, as observed in this study, should 







4.3.4 Characterization of Free LC in Serum 
 The serum sample from the same patient collected at the same clinical visit was 
also analyzed. Free LC proteins were immunoprecipitated from 40 µL serum (Figure 4.20 
[a]). Following in-gel digestion with trypsin, the tryptic peptides were first analyzed by 
MALDI-TOF MS (Figure 4.20 [b]), followed by LC-MS/MS for identification of the 
peaks. Full sequence coverage was obtained by combining both sets of data. Tryptophan 
oxidation was observed. However, no tyrosine chlorination or lysine oxidation products 
were observed. This result may be due to a low concentration of modified amino acids in 
the circulation. However, since the epitopes for the free LC antibody were located in the 
CL region, it is quite possible that some forms of the Ig LC protein with truncated C-
terminals were not recognized and therefore not precipitated. More research is required to 
determine whether exposure of the amyloidogenic LC protein to HOCl happens before or 




Figure 4.20 Characterization of serum free LC of the same patient as the Ig LC 
AL01-068. The free LC was immunoprecipitated and subjected to 2D-PAGE separation 
as shown in [a], which produced significant spots with apparent molecular weights 
around 25 kDa. The spots were picked and digested with trypsin. The MALDI-TOF mass 
spectrum for the darkest spot is shown in [b]. T: trypsin autolysis peak. 
 
4.4 Conclusions 
In this chapter, urinary Ig LC AL01-068 purified from a patient diagnosed with 
AL amyloidosis was characterized. Bottom-up MS analysis indicated that this protein 








chlorinated, while several lysine residues had the side chain primary amine converted to a 
nitrile group. In vitro experiments showed that HOCl produced by the MPO-H2O2-Cl
-
 
system might be responsible for these modifications. Intact LCs immunoprecipitated 
from serum, collected on the same patient at the same clinic visit, did not exhibit similar 
modifications to tyrosine and lysine residues. More research will be required to elucidate 
the potential for exposure of amyloidogenic LC proteins to HOCl, to determine when it 
may occur and the possible consequences of these modifications. Further, dichlorinated 
tyrosine residues and lysine residues with a nitrile group at the side chain are promising 
candidates for biomarkers of HOCl, in addition to the currently recognized 







Characterization of Plant-Derived Antibody Mixture 
 
5.1 Introduction 
The history of exploring plants as expression platforms for foreign proteins 
including therapeutic mAbs, spans more than two decades 
(288, 289)
. Plants, as eukaryotes, 
can produce properly folded and assembled proteins 
(290)
. Gene-engineered plants also 
have the ability to perform mammalian types of glycosylation, which is essential for the 
proper functioning of an antibody molecule 
(36, 291-293)
. More importantly, the plant system 
is commercially attractive with its lower cost requirement when compared to establishing 
and culturing stable mammalian cell lines or using transgenic animals. However, the 
observed yield of mAbs in plants is low, probably due to an apparent protein instability 
and degradation problem 
(294-296)
; low yield is likely one critical factor responsible for 
delaying wider spread of this method. In particular, two to five major fragmented mAb 
species commonly occur after non-reducing gel separation and Western-blotting analysis 
of different antibodies expressed and extracted from Nicotiana tabacum leaves 
(297-302)
. 
These degradation products can be difficult to remove and compromise efficiency of the 
therapy. Characterization of these mAb fragments is the first step to a better 
understanding of the degradation process, i.e. to answer the questions as to when and how 
the mAb becomes degraded. Improvement in purification and analysis procedures may be 




it is always necessary to evaluate each batch of the produced mAbs to check for possible 
modifications and insure stable product qualities. 
Commonly produced therapeutic mAbs are of IgG type, having two LCs and two 
HCs with conserved N-glycosylation sites in the constant domain of the HCs. An intact 
antibody molecule, with a molecular weight around 150 kDa, can be difficult to 
characterize fully. The mAb mixture extracted from plants contains multiple fragmented 
species, adding more difficulty to the analysis process. Usually, these samples are 
analyzed by enzyme-linked immunoassay (ELISA) or SDS-PAGE followed by 
immunoblotting to gain complex composition information 
(301-303)
.  MS based methods 




There is a great need for inexpensive medication for prophylaxis against this 
virus, considering the epidemic levels of sexually transmitted disease (STD), especially 
in developing countries. The HSV8 Ab is designed to neutralize human herpes simplex 
virus 1 and 2 (HSV-1 and HSV-2), which may also promote the spread of human 
immunodeficiency virus (HIV). A drug with multiple purposes is being developed, which 
contains both HSV8 and Abs against HIV and will be administrated in a form of films. 
To minimize the cost, the HSV8 Ab is tested to grow in transgenic tobacco plants. In this 
study, we carried out various experiments to characterize the heterogeneity of this plant-
derived mAb sample, which might also benefit production of other therapeutic mAbs in 
plants. Samples with or without reversed-phase HPLC fractionation were subjected to 




some experiments, the sample was directly analyzed by mass spectrometry after simple 
reduction and alkylation treatment (to separate the HCs and LCs). The replacement of 
two serine residues in each LC was detected; consultation with the producers revealed 
that such an alternative sequence was also in use in their plant. Three N-terminal 
fragments and one C-terminal fragment of the HC were observed; their presence could 
result from cleavage at sites inside or surrounding the hinge region. Other PTMs of the 
protein processing pathway were also found, including N-terminal pyroglutamate 
formation, C-terminus lysine removal, asparagine deamidation, and 
methionine/tryptophan oxidation. The presence of these PTMS is potentially problematic 
and deserves more attention during mAb design to guarantee stable drug production. N-
glycan analysis indicated that there were multiple glycoforms, the most abundant having 
the composition of (HexNAc)2(Man)3(GlcNAc)2. 
 
5.2 Methods and Experiments 
Sample characterization methods are summarized in Figure 5.1. For glycan 
analysis, N-glycans were released by PNGase F. Both native and permethylated N-
glycans were detected by a MALDI-TOF MS and further analyzed with tandem MS on 
an ESI-FT-MS. The mAbs with/without C4-HPLC separation were loaded to SDS-PAGE 
gels under both non-reducing and reducing conditions. The mAb treated by PNGase F 
was also separated by a reducing gel to determine which bands contained the 
glycosylated species. Alternatively, the mAb mixture was first reduced and alkylated, and 




fractionated by C18-HPLC and SDS-PAGE. Bottom-up MS analyses were performed for 
selected gel bands.  
 
 
Figure 5.1 Summary of the major sample characterization methods for sample 






5.2.1 Antibody Preparation 
The antibody was produced by Kentucky BioProcessing (KBP). It was cultivated 
in and extracted from tobacco plants, which were genetically-engineered to possess only 
mammalian glycotransferases. The stock protein solution had a concentration of 20 
mg/mL and was stored at -80 
o
C prior to use. 
 
5.2.2 N-glycosylation Analysis 
For N-glycosylation, the glycosylation site is located within the conserved 
sequence N-X-S/T, where X cannot be a proline residue 
(26)
. Based on this, considering 
the target protein sequence, the antibody should have just one potential N-glycosylation 
site located on each IgG HC (asparagine 305). The N-glycans were released with PNGase 
F (New England Biolabs) according to the provided protocol. Enzyme was added using a 
weight ratio of 1:20 to the denatured antibody and the reaction was run overnight at 37 
o
C. The incubation mixture was adjusted to have 2% methanol and 0.1% FA before the 
products were separated by passage over a C4 Micro SpinColumn
TM
 (the Nest Group). 
The glycans and salts should not be retained and thus, can be separated from the proteins 
and detergents. Subsequent desalting of the glycans was performed with a PD MiniTrap 
G-10 column (GE Healthcare) according to the manufacturer’s instructions. 
Purified native glycans were divided into two equal parts. One part was first 
checked with ultrafleXtreme™ MALDI-TOF/TOF MS to verify the success of the glycan 
release. The other half was dried with a SpeedVac and permethylated with a solid phase 
method using a spin-column 
(305)




then packed with NaOH beads. After the can was discarded, the column was washed with 
200 μL dimethyl sulfoxide (DMSO) and then filled with another fresh 200 μL of DMSO 
until the sample was applied. Dried N-glycan was re-suspended in a solution of 70.8% 
DMSO, 26.4% iodomethane (CH3I) and 2.8% water and applied to the column by 
centrifugation at 150 rcf for 30 s. The sample was passed through the column multiple 
times. Finally, to ensure complete sample recovery, 100 μL ACN was added and the 
column was centrifuged at 1000 rcf for 30 sec. Permethylated glycans were transferred to 
a glass tube and extracted with 100 μL chloroform and 100 μL water. The organic layer 
was washed several times with water until the water layer reached a neutral pH. The 
organic layer was dried with a SpeedVac and the product was re-dissolved in 50% 
methanol prior to MALDI-TOF MS analysis. 
The ultrafleXtreme™ MS was operated in the positive ion, reflectron mode, with 
DHB as the matrix. The data were searched with the GlycoMod tool (ExPASy: 
http://web.expasy.org/glycomod/). Permethylated glycans were also analyzed with 
tandem MS using a 12-T solariX
TM
 hybrid Qh- FTICR mass spectrometer (Bruker 
Daltonics). The sample with/without PNGase F treatment was also checked with the 
ultrafleXtreme™ MS for glycosylated components.  
 
5.2.3 SDS-PAGE Analysis 
Precast NuPAGE
®
 bis-tris gels were purchased from Life Technologies, which 
were 1.0 mm thick with a gradient of 4-12%. Ten mM DTT was added to the sample for 




When PNGase F treatment was followed by an SDS-PAGE analysis, either 1 μL 
PNGase F (Promega) was added to 20 μg sample or 0.5 μL of this enzyme was added to 
the HPLC fraction in a buffer of 50 mM ABC and 0.05% ProteaseMAX
TM
 surfactant 
(Promega), which was then incubated at 37 
o
C for 18 hr. Samples treated the same way 
without PNGase F were used for comparison. 
 
5.2.4 Top-down MS Analysis of Intact Antibody 
The antibody sample was diluted to a final concentration of 5 μg/μL with 100 mM 
ABC and then reduced with 5 mM DTT at 56 
o
C for 1 hr. After the solution was cooled 
to room temperature, iodoacetamide was added to a final concentration of 14 mM and the 
sample was kept in the dark for 30 min before additional 5 mM DTT was added to 
quench excess iodoacetamide. The mixture was dialyzed against ultrapure water in a 
dialysis cassette with a MWCO of 3.5 kDa (Pierce) at 4
 o
C, overnight. After dialysis, the 
sample was further desalted with a C4 Ziptip
®
 (Millipore) according to the instructions 
and analyzed using a 12-T solariX
TM
 hybrid Qh- FTICR mass spectrometer (Bruker 
Daltonics). The desalted sample was dissolved in a solution containing 50% ACN and 
0.1% FA to a concentration of 5 pmol/μL, and introduced into the instrument via a 
nanoESI source. The instrument was operated in the positive ion mode and was 
externally calibrated with sodium-trifluoroacetic acid (STFA) clusters before use. For 
tandem MS analysis, precursor ions were selected and fragmented by CID activation. 





5.2.5 Reversed Phase HPLC Separation   
The antibody sample was reduced and alkylated under similar conditions with the 
addition of 8M urea and a shortened reducing time of 45 min. The dialyzed sample was 
lyophilized and reconstituted into a solution of 85% buffer A (H2O + 0.5% acetic acid 
(AcOH)/0.05% TFA (v/v)) and 15% buffer B (80% n-propanol + 10% H2O + 10% ACN 
+ 0.5% AcOH/0.05% TFA (v/v)) before being loaded onto an Agilent 1200 series HPLC 
equipped with an Agilent Zorbax 300SB-C8 column (5 μm particle size, 4.6 mm X 150 
mm). The column was operated at 70 
o
C with a flow rate of 1 mL/min. Separation was 
accomplished with a gradient elution: 0-2.5 min: 15% buffer B; 2.5-15 min: 15-35% 
buffer B; 15-16 min: 35% buffer B; 16-18 min: 35- 90% buffer B; 18-20 min: 90-15% 
buffer B. 
The antibody sample without any treatment was also dialyzed, lyophilized, 
reconstituted, and loaded onto the same column. For separation of this sample, buffer A 
was 98% H2O + 2% isopropanol (IPA)/0.1% TFA while buffer B was 10% H2O + 70% 
IPA + 20% ACN + 0.1% TFA. The intact antibody sample was re-suspended with 80% 
buffer A and 20% buffer B. The column was operated at 80 
o
C with a flow rate of 0.8 
mL/min. Separation was carried out with a gradient elution: 0-2.5 min: 20% buffer B; 
2.5-15 min: 20-50% buffer B; 15-16 min: 50% buffer B; 16-17 min: 50-90% buffer B; 
17-18 min: 90-20% buffer B. 
Separation conditions were adapted from Agilent application notes. The UV 
monitor was set 214 nm. After each run, the column was balanced before another run. 




Bottom-up MS analysis methods were as described in Chapter 2. MALDI-TOF 
MS analysis was performed on an ultrafleXtreme™ MS (Bruker Daltonics). Tandem MS 
analysis was performed with an ESI-LTQ-Orbitrap XL™ MS (Thermo Fisher Scientific) 
coupled to both a nanoACQUITY UPLC
®
 system (Waters) and an Advion TriVersa 
NanoMate™ system (Advion Biosciences), with CID as the dissociation mode, and the 
ions were detected either in the LTQ or the orbitrap. Tandem MS data were analyzed 
using the SEQUEST search function of Proteome Discoverer 3.0 (Thermo Scientific) 
against the defined antibody sequence and the results were checked manually. Chapter 2 
details the search parameters that were used. 
 
5.3 Results and Discussion 
5.3.1 N-glycan Characterization of the Antibody 
The N-glycan pool was released from this antibody sample. The glycans were 
analyzed in both native and permethylated forms using a MALDI-TOF MS instrument 
(Figure 5.2). The data search results with the GlycoMod tool (ExPASy: 
http://web.expasy.org/glycomod/) indicated a total of six glycoforms. For each native 
glycoform, the corresponding permethylated form was detected. The most abundant peak 
([M + Na]
+
) observed for the native glycans was at m/z 1339.583 and for the 
permethlyated glycans at m/z 1661.920. These results suggested the possible composition 
of (HexNAc)2(Man)3(GlcNAc)2, including the chitobiose core; this was confirmed by 
tandem MS analysis of the permethylated glycans with CID activation (Figure 5.3). The 




and Costello in 1988 
(306)
. Two precursors had so close m/z values that they were isolated 
and fragmented at the same time, namely, the fully permethylated glycan charged with 
one proton and one sodium and the byproduct with one methyl group fewer, charged with 
one proton and one potassium. 
Native glycans usually have poor ionization efficiency in either MALDI or ESI 
sources. Permethylation of glycans is the most common derivatization method which 
substitutes a methyl group (+14 Da) for the proton in each hydroxyl group of the 
saccharide residues. This can not only alleviate the low ionization efficiency but also 
improve the sugar stability and assists in the determination of linkage sites. However, the 
glycans can be incompletely permethylated as seen in Figure 5.2. More complete 
derivatization may be achieved by several rounds of permethylation. The +30 u peaks 
observed in permethylated samples corresponded to byproducts previously reported 
(307)
. 
The permethylation reagents, CH3I and DMSO, produced iodomethyl methyl ether 






Figure 5.2 MALDI-TOF mass spectra for both [a] native and [b] permethylated 
glycans released by PNGase F from the antibody. Peaks for glycans were sodiated ([M 
+ Na]
+







Figure 5.3 ESI-CID-MS/MS spectrum of the [M + Na + H]
2+ 
and [M - CH2 + K + 
H]
2+
 ions of the major permethylated glycan released from HSV8-N antibody. This 
result suggested the possible composition of (HexNAc)2(Man)3(GlcNAc)2. Peaks labeled 
with (+Δ) are not fully permethylated (one methyl group fewer) and are potassium 
adducts. Singly charged ions are sodium adducts if not labeled with (+K), which are 
potassium adducts. Doubly charged ions are charged with one sodium and one proton if 
not otherwise labeled. “+CH2” means one more methyl group. 
 
The antibody was cultured in plants with mammalian glycan transferases, it was 
then highly possible the major glycan species had the linkage as shown in Figure 5.3. 





Electronic excitation dissociation (EED) experiments of the doubly charged 
permethylated glycan ([M+2Na]
2+
) were attempted to deduce the linkage information 
(Figure 5.4). The 
0,4
A3 ion is a diagnostic ion for α1-6 linkage. The presence of 
3,5
A3 ion 
suggests another linkage as α1-2 or α1-3. A fragment with 0,2 cross-ring cleavage is 
required to differentiate this two types, which, unfortunately, is not observed. ETD 
fragmentation was also performed, which offered no more information. There is no 
evidence to support the β1-2 or β1-4 linkages, either. 
It has been reported in the literature that removal of core α1,3-fucose in plant-
derived antibodies and mammalian core α1,6-fucose in CHO-derived antibodies will 
improve antibody binding to receptors on cells and thus, enhance the antibody-dependent 
cell-mediated cytotoxicity (ADCC) 
(36, 37)
. The designed mAb, which only has one N-
glycosylation site in each HC, has mammalian-like glycans without any core 
modification. This eliminates the immunogenicity due to plant-specific glycoforms and 



























































































5.3.2 Sequence Verification 
The antibody sample was separated with SDS-PAGE (4-12%) under both non-
reducing and reducing conditions (Figure 5.5). With 20 μg of protein loaded in each lane, 
there were 11 bands observable under non-reducing conditions after Coomassie staining, 
with molecular weights ranging from a little above 150 kDa to slightly less than 25 kDa. 
Under reducing conditions, only three bands were observed. Besides the bands expected 
for the HC and LC, an additional protein band with an apparent molecular weight of 
approximately 28 kDa was observed. Sample mixtures with PNGase F treatment were 
also loaded on gels for comparison. Bands 1 to 7 (Figure 5.5 [a]), the HC band and the 
extra band (Figure 5.5 [b], 10 μg each lane) showed mass shifts after treatment with the 
endoglycosidase, indicating the presence of N-glycans. The presence of sugar moieties in 
the top three bands were further confirmed by a MALDI-TOF MS analysis (Figure 5.5 
[c]). It’s highly possible that major components of bands 1-3 were fully assembled 
glycosylated antibody, two LCs plus one HC and some HC fragments, and two HCs plus 




Figure 5.5 SDS-PAGE gels (4-12%) of HSV8-N under different conditions. [a] 
Separation of a 20-μg sample under non-/reducing conditions [b]Separation of a 10-μg 
sample with or without PNGase F treatment under reducing conditions. “*” indicates the 
band corresponding to PNGase F. Gels were visualized with Coomassie stain. 
 
Tryptic peptides from all three bands (Figure 5.5 [b], reducing condition without 
PNGase F) were analyzed by MALDI-TOF MS and ESI-LC-LTQ-Orbitrap MS with CID 
activation and detection in the orbitrap. HC C-terminal peptides with or without the C-
terminal lysine residue (peptides [448-455] and [448-454, respectively]), although not 
detected by MALDI-TOF MS, were observed and confirmed by ESI-LC-CID-MS/MS in 
both the HC band and the extra band (Figure 5.6). Otherwise, the HC sequence was no 
different from the one expected from the cDNA sequence. Two amino acids in the LC 





sequence. CID spectra of [M + 2H]
2+
, m/z 765.3887 (peptide [170-183]) and [M + 2H]
2+
, 
m/z 716.8535 (peptide [191-202]) (Figure 5.7) demonstrated replacements of serine 177 
with an asparagine residue and serine 202 with an arginine residue, respectively. 
Further, antibody sample reduced and alkylated without denaturation by urea was 
loaded onto a solariX
TM
 ESI-FT-MS (Figure 5.8). After spectra deconvolution, the data 
showed the most abundant peak to be at [M + H]
+
 m/z 23427.63766; this finding was 
close to that expected for LC (theoretical [M + H]
+
 m/z 23278.54496 in the native form, 
23563.65228 with all five cysteine residues carbamidomethylated). A peak with a 20+ 
charge was isolated and fragmented using CID activation (Figure 5.9). It seemed that 
only cysteine 214 at the C-terminus was modified while the other four cysteines still 
formed two pairs of disulfide bonds (theoretical [M + H]
+
 m/z 23427.61510); this 
confirmed the amino acids replacements in LC sequence. No information for the HC was 
available using this approach, possibly due to heterogeneity both in the protein and 
glycan structures. 
MALDI-TOF mass spectrum of tryptic peptides derived from the extra protein gel 
band showed sequence peptides from both chains (Figure 5.10). The sequence coverage 
was confirmed by ESI-LC-CID-MS/MS analysis. HC peptides mainly from the N- and C-
termini regions were obtained. It seemed that this plant-derived mAb extraction was a 
complicated mixture with non-fully assembled Ig intermediates and/or fragments. 
Multiple truncated species originating from the HC must be present. 
Bands 1-11 in Figure 5.5 [a] (without PNGase F) were also analyzed with bottom-




were dominated by HC peptides. Bands 8-11, which were dominated by LC peptides, 
also showed some tryptic peptides from HC. 
Figure 5.6 HC C-terminal peptides [a] with and [b] without lysine 455 processed 
were present in both the HC band and the extra band of Figure 5.5 [a]. Here showed 
ESI-LC-CID-MS/MS spectra of [M + 2H]
2+







Figure 5.7 Two serine (S) residues expected from cDNA sequence of the LC were 
replaced. CID spectra of [a] [M + 2H]
2+
 m/z 765.3887 and [b] [M + 2H]
2+
 m/z 716.8535 
confirmed an asparagine (N) at position 177 and an arginine (R) at position 202, 








 ESI-FT-MS analysis of the reduced and alkylated antibody 












Figure 5.9 (following page) ESI-CID-MS analysis of the peak with 20+ charge in 
Figure 5.8 on SolariX
TM
. The major species thus was confirmed as a non-fully reduced 


















Figure 5.10 (following page) MALDI-TOF mass spectrum for the tryptic peptide 
mixture derived from the band with truncated species in Figure 5.5 [b]. The 
sequence coverage of the antibody HC indicated by this spectrum is shown below. Extra 
covereage, as confirmed by tandem MS analysis, is labeled with dashed lines. Peptide [1-
12] had pyroglutamate at the N-terminus. Some methionine residues were oxidized 


















5.3.3 Characterization of Reduced and Alkylated Antibody Sample 
To get more detailed information on the truncated species, 20 μg of this antibody 
sample was reduced and alkylated under denaturing conditions, dialyzed and separated on 
a C8 column (Figure 5.11 [a]). The chromatogram contained two major peaks, each 
surrounded with shoulder peaks. The fractions were separated by SDS-PAGE (Figure 
5.11 [b]), in-gel trypsin digested, and analyzed by MS and MS/MS. 
No truncated forms of the LC were found. Fractions L1 and L3 eluted faster and 
slower than the major LC fraction (L2), respectively. MALDI-TOF mass spectra of band 
L1b in fraction L1 and fraction L3 (Figure 5.11) revealed single modifications of LC 
peptides in each. The former one had a single asparagine residue deamidated in LC 
peptide [127-142] ([M + H]
+
, m/z 1798.879); the latter had a carbamylated N-terminal 
([M + H]
+
, m/z 1927.012), possibly generated by a side reaction with urea during heating. 
The modifications were confirmed by ESI-LC-MS/MS (CID fragmentation and detection 
in the LTQ). Both modifications would alter the charge states of the protein and thus, 





Figure 5.11 C8-HPLC separation of the reduced and alkylated antibody mixture 
prepared under the denaturing conditions. Five fractions were collected and 
visualized on an SDS-PAGE gel (4-12%). “*” indicates a faint band at the left side. Upon 
PNGase F treatment, band L1a was shifted but not band L1b [c]. “*” indicates a faint 
















































































































































Band L1a with a higher molecular weight than that of LC also showed up in 
fraction L1. In-gel tryptic digestion followed by MALDI-TOF MS and ESI-LC-MS/MS 
(CID fragmentation and detection in the orbitrap) analyses confirmed the presence of C-
terminal HC fragments in this band (Figure 5.13). The assignments of peptides [353-368] 
(theoretical [M + H]
+
 m/z 1872.9702) and [401-417] (theoretical [M + H]
+
 m/z 
1873.9218) in the MALDI-TOF mass spectrum were based on the tandem MS analysis. 
The ESI-LC-MS/MS analysis confirmed a sequence coverage of amino acids [230-455], 
containing the N-glycosylation site (asparagine 305), as a mass shift was shown with 
PNGase F treatment (Figure 5.11 [c]). The molecular weight for the truncated HC [230-
455] with modified cysteines and attached N-glycan was approximately 27 kDa. 
Considering the change in electrophoretic migration behavior resulting from the N-
glycosylation, the truncated HC species L1a may be a fragment that begins with lysine 
230 and possesses a (non-) processed C-terminal. Methionine residues 260 and 436 were 






Figure 5.13 MALDI-TOF mass spectrum of tryptic peptides of band L1a (Figure 
5.11). Extra coverage as confirmed by tandem MS analysis was labeled with dashed 







Trace amounts of HC fragments and LC were found co-eluted in the major HC 
peak (bands H1a and H1b, Figure 5.14). In addition, the shoulder peak which followed 
the major HC peak, contained a small portion of the intact protein (band H2a) plus three 
weak fragment bands (H2b-d) (Figure 5.15). All three fragments contained N-terminal 
peptides of the HC with terminal glutamine exclusively converted to pyroglutamate. 
MALDI-TOF mass spectra for bands H2b, c, and d showed sequence coverage of amino 
acids [1-278], [1-256], and [1-155], respectively. Without accounting for potential PTM 
of cysteine residues, the corresponding molecular weights for these peptides should be 
29.8, 27.3, and 16.3 kDa. Peptide [1-278] ended with an aspartic acid residue (followed 
by a proline residue in the sequence) while the other two ended with trypsin-recognized 
lysine residues. It must be noted that trypsin cleavage between residues 155 and 256 
would produce a very long peptide [156-218] (6712.31 Da) followed by three short 
peptides each with only four amino acid residues, which would not be good candidates 
for MALDI-TOF detection. No proper proteases were available to address this situation. 
The actual truncation sites (ending residues) for bands H2c and H2d might lay beyond the 
trypsin recognition sites. It is possible that band H2d contains the complementary part of 
the C-terminal fragment, which would have a molecular weight of 24.3 kDa. More 
methionine resides (residues 48, 52, and 102) were found oxidized. Moreover, it seemed 
that fraction H2 had a high level of dioxidized tryptophan 36. An asparagine residue 
followed by a glycine residue has been reported to have a faster deamidation rate 
(256)
 and 
there are two such asparagine residues (asparagine 323 and 392) in the HC. However, 




truncated HC proteins (see enlarged isotope distributions in Figures 5.13 [b] and 5.15 
[b]). 
The longest N-terminal fragment resulted from peptide cleavage between aspartic 
acid 278 and proline 279, which is well-known to be susceptible to cleavage 
(308)
. The 
longest C-terminal fragment resulted from peptide bond cleavage between aspartic acid 
229 and lysine 230, both located in the hinge region of the HC. The hinge region of an 
antibody is a less structured region of the molecule and thus more accessible to proteases 
and more likely to be cleaved 
(309-311)
. Fortuitously, these two fragments shared similar 
electrophoretic mobilities and thus, the signals from their tryptic peptides would have 
contributed to the sequence coverage (Figure 5.11) for the extra band observed on the gel 
shown in Figure 5.5 [b] that was developed under reducing conditions. For formation of 
H2c (Figures 5.11 and 5.15), the cleavage site should be somewhere between lysine 256 
and aspartic acid 278, i.e. downstream of the hinge region. The absence of a 
complementary HC fragment implied a possible further degradation after the formation 
of H2b. Such was the case for H2c (Figures 5.11 and 5.15). However, considering the 
apparent molecular weight, it was still possible that the hinge region cleavage mentioned 
above was also responsible for the formation of H2d. With the method used here, the 
small fragments would not be retained on the C8 column that was used and would likely 
run off the gel without being detected.  
To summarize, a total of three N-terminal fragments and one C-terminal fragment 



































































































































Figure 5.15 (following page) MALDI-TOF mass spectra of tryptic peptides of bands 
H2a-d (Figure 5.11 [b]). Bands H2b to d had sequence coverage of amino acids [1-278], 
[1-256] and [1-155], respectively. [b] Expressions of the regions around two peaks show 
the isotopic distributions in H2a of [a]. N-terminal glutamine (Q) was exclusively 
converted to pyroglutamate in all four bands. Some methionine and tryptophan residues 





















5.3.4 Characterization of Intact Antibody 
The dialyzed intact antibody sample was fractionated on the same C8 column 
(Figure 5.16 [a]) used in the previous studies. Fractions were visualized by Coomassie 
staining of the SDS-PAGE gel (4-12%) (Figure 5.16 [b]). For the same fraction, equal 
amounts of proteins were loaded for separation under non-reducing and reducing 
conditions. Fraction 1 was well separated from other peaks although low in abundance; 
fraction 3 contained the major peak. For both conditions, fraction 1 was from a protein 
load of 50 μg, fraction 3 from protein load of 6 μg; all other fractions were from a protein 
load of 30 μg.  
Fraction 1 showed a major gel band corresponding to a molecular weight above 
50 kDa (band a), which was reduced to band g (band 6 in Figure 5.5 [a]) with DTT 
treatment. Fractions 2 to 5 contained multiple species which were composed of HC 
and/or LC and/or HC fragments. Fraction 2 had a well-resolved band b (band 2 in Figure 
5.5 [a]), which might have been masked in fraction 3, as well as a relatively high 
abundance band c (band 4 in Figure 5.5 [a]) with a molecular weight above 100 kDa. 
Fractions 3 to 5 also had two faint double bands (band f in dashed square, bands 9 and 10 
in Figure 5.5 [a]) that migrated to similar positions on the gel. Band 11 might be too faint 
to be visualized here. Bands d and e (band 8 in Figure 5.5 [a]) displayed comparable 
mobilities on the 1D gel and showed similar MALDI-TOF mass spectra with mostly LC 
peaks plus some N-terminal HC peaks. The higher abundance of band e might be 






Figure 5.16 C8-HPLC separation of the antibody mixture without reduction or 
alkylation. Five fractions were separated and visualized with Coomassie blue stain on an 








MALDI-TOF mass spectra for bands g and h were similar (Figure 5.17). The 
MALDI-TOF mass spectrum obtained for band g showed a coverage of [230-447] ([230-
455] by tandem MS) of HC. The acidic N-terminus peptide was not readily seen in the 
MALDI mass spectrum. However, in addition to the C-terminal peaks, the MALDI mass 
spectrum of band h showed some additional peaks corresponding to the N-terminal 
region of the HC, indicating an incorporation of N-terminal fragments in the complexes 
of fraction 2. MALDI-TOF mass spectra for bands e, f, and i were dominated by LC 
peptides (Figure 5.18). Still, bands e and i provided evidence for several N-terminal HC 
peptides with a coverage of [1-155] of HC in band e. The most abundant HC peaks in 
Figure 5.17 (H[283-296], H[353-368] and [401-417]) also appeared in bands i and f, 
perhaps due to their high ionization efficiency and the presence of some HC fragment 
bands. It was possible that all three bands travelled close to some (mostly N-terminal) HC 
fragment bands.  
Based on the mass spectral data and gel information yielding apparent molecular 
weights, we proposed assignments for the complexes shown in Figure 5.5 [a] as 
following: band 1, mostly a fully assembled and N-glycosylated HSV8-N Ab; band 2, a 
complex of two LCs plus one HC and some (mostly C-terminal) HC fragments; band 3, a 
complex of two HCs plus one LC; band 4, a HC dimer travelling close to a complex of 
one LC plus one HC and some (mostly C-terminal) HC fragments; band 5, a complex of 
one HC plus one LC; band 6, a dimer of C-terminal HC fragment travelling close to a 




travelling close to a dimer of N-terminal HC fragment; bands 9-11, LC travelling close to 
small amounts of some HC fragments. 
 
 
Figure 5.17 MALDI-TOF mass spectra for bands g and h in Figure 5.16 [b], which 
looked similar. However, in addition to the C-terminal peaks (with a coverage of [230-
447] in band g), band h also showed some extra peaks that derived from the N-terminal 
region of the HC (in bold font), indicating an incorporation of N-terminal fragments in 









Figure 5.18 (following page) MALDI-TOF mass spectra for bands e, i and f in 
Figure 5.16 [b] were all dominated by LC peaks. HC peptides are labeled in bold font. 





















Just as many recombinant mAbs produced and extracted from plants, this sample 
was a complicated mixture (Figure 5.5 [a]). Reversed-phase HPLC separation of the 
intact mAb sample with a C8 column could remove only a very small portion of the 
fragments, e.g. band 6 and part of band 4 in Figure 5.5 [a], if the first two fractions were 
discarded. Furthermore, bands in Figure 5.16 with molecular weights higher than that of 
the intact mAb indicated formation of aggregated products during separation since the 
column was used at 80 
o
C. To produce a sample with a higher concentration of the 
effective intact mAb, it is important to know the nature of the intermediates and/or the 
degradation products, in order to devise means to prevent their formation. 
There have been several proposed explanations for the presence of multiple 
species in the plant-derived mAbs. Recent evidence indicates that the fragments are due 
to proteolytic degradation within the plants. Neither the extraction process, when tissues 
get disrupted and release subcellular proteases, nor the commonly used extraction 
conditions are major concerns 
(302)
. It has been proposed that the proteolysis mostly likely 
occurs during transit of the protein between the endoplasmic reticulum (ER) and the 
Golgi during biosynthesis of the fully assembled antibody molecules, since an inhibitor 
of Golgi vesicle formation will prevent IgG1 degradation in certain plants 
(301)
. For the 
mAb sample studied here, which is derived from tobacco plants, it remains possible that 
some fragments are assembly intermediates released from intracellular spaces during 
extraction. Furthermore, the truncated HC species observed during these analyses could 






A therapeutic HSV8-N mAb has been successfully produced in tobacco plants 
with mammalian glycoforms. The sample complexity may be the result of enzymatic and 
non-enzymatic peptide bond cleavages in the hinge region and the surrounding area of 
the HC (Figure 5.19). Although the test sample was stored at -80 
o
C, some protein 
degrading modifications may have occurred prior to storage, including N-terminal 
pyroglutamate formation, C-terminal lysine processing, asparagine deamidation, and 
methionine/tryptophan oxidation. MS methods have proven to be useful tools for the 
structural characterization of therapeutic mAbs, which will finally contribute to the 
production of more stable mAbs in plants with a higher efficiency. 
 
 
Figure 5.19 HC fragments ending/starting points observed in this study. Actual 
cleavage sites might be several residues away. The hinge region is composed of peptides 










Chapter 6  
 
Conclusions and Future Perspectives 
 
6.1 Conclusions 
Human Ig is a group of glycoproteins that are critical players in the immune 
system. Its diversified sequences greatly benefit the capability of recognizing and 
destroying invading pathogens. On the other hand, Ig LCs can aggregate and form β-
sheet featured structures, which can deposit in multiple organs throughout the body and 
cause problems. This sequence variability, especially in the VL region of a LC protein, 
presents analytical challenges in the analysis of antibodies. For completion of this 
dissertation great effort has been expended in exploring the application of MS-based 
methods to amyloidogenic LC studies, including de novo sequencing and characterization 
of PTMs, which can help to elucidate the sequence/structure factors important for the 
formation of LC amyloid fibrils. In addition, HPLC-based separation and MS-based 
analysis have been utilized to characterize a plant-derived HSV8-N mAb mixture. 
The most important experimental scheme used during the research reported in this 
dissertation contains several steps: 2D SDS-PAGE protein display, in-gel enzymatic 
digestion, MALDI-TOF MS analysis and/or various tandem MS characterizations. In 
Chapter 1, amyloidogenic LCs extracted from a fat aspirate were de novo sequenced by 
ESI-(LC)-MS/MS. Fragmentation methods using HCD, CID, and ETD provided 




be used for very small amounts of starting material; the lower limitation is set by the 
sensitivity of the MS instrument which can be as low as 50 fmol, the sensitivity achieved 
with the LTQ-Orbitrap XL used in these studies. LCs fragments in this fat sample 
contained truncated C-terminals; these data do not exclude the possibility that the N-
terminal may also be processed.  
In Chapter 2, a study was conducted on samples collected from five patients 
diagnosed with AL amyloidosis featuring of λ6LC subtype including serum, kidney,  and 
urine. Free circulating LCs or LCs in the bound form (IgG or IgA) in the serum samples 
were found to be exclusively full-length proteins. Deposited LCs consisted mostly of N-
terminal fragments; only a very small amount of full-length LC was observed in one 
sample. The urinary LCs, available from two patients, were found to be partially trimmed 
at their N-termini. Thus, it is quite possible that fragmentation of LC proteins occurs after 
amyloid deposition in tissues and organs. Whether fragmentation is necessary for 
initiation of the fibrillogenesis process remains to be determined. 
So far, the major PTM of amyloidogenic LCs appears to be truncation. For other 
PTMs observed, including asparagine deamidation, methionine and tryptophan oxidation, 
all of which may alter the local charge distribution, it is hard to differentiate in vivo 
modifications from potential handling artifacts. Other than the extent of truncation, the 
PTMs from different types of samples available from the same patients were similar. 
However, the investigation of one urinary λ2LC did indicate mono-/di- chlorination of 
some tyrosine residues and nitrile formation from the primary amine on the lysine side 




monochlorinated tyrosine residue has been used as biomarker for HOCl exposure; these 
two additional modifications could also be considered potential markers. No similar 
modifications of tyrosine or lysine residues were found in the serum sample collected at 
the same time from the same patient. 
Igs or mAbs are becoming widely used as therapeutics. In Chapter 5, both top-
down and bottom-up MS approaches were adopted to evaluate a mAb mixture produced 
in tobacco plants, and these approaches proved to be an efficient means by which to 
check the amino acid sequence and N glycoform distribution. After separation with C8-
HPLC, three N-terminal fragments and one C-terminal fragment of the HC were 
determined to be present in the sample. This result shows that the method can be useful to 
understand the fragmentation process often observed when mAbs are expressed in plants 
and thus, the information provided here may benefit mAb design and production. This 
method can also be extended to analyze antibodies in general for quality control, 
evaluation of stability, and other parameters. 
In conclusion, the study in this dissertation expands our knowledge of 
amyloidogenic LCs, AL and Igs.    
 
6.2 Future Perspectives 
The bottom-up MS approach with 2D SDS-PAGE protein display gives intuitive 
assessment of the extracted proteins. However, the handling process (both extraction and 
purification steps) can introduce some bias or artifacts, not to mention the limits in 




amyloidosis have been archived in the form of FFPE tissue blocks. Protein extraction 
from this type of sample followed by MS characterization is possible, but it can suffer 
from problems similar to those mentioned above. Therefore, it will be a good attempt to 
develop alternative methods for direct sampling from the tissue surfaces. Tissue imaging 
with a mass spectrometer, especially MALDI-TOF MS, is a rapidly expanding field. It 
has been used in the analysis of amyloid tissue sections, including brain tissues with 
amyloid β (Aβ) and other tissues containing LC or TTR amyloid deposits (240, 241, 244). So 
far, researches are focusing on the protein identification or amyloid protein classification. 
It will be more helpful to extend the application to direct PTM analysis, or direct 
comparison of different tissues from the same patient or the same types of tissues from 
both patients and matched controls. This may be achieved with tandem MS, using either a 
MALDI MS or ESI-MS/MS instrument. In addition, MS imaging with an ICP MS may 
offer further information on metal ion deposition. For example, three histidine (H) 
residues in the N-terminal hydrophilic region of Aβ provide primary metal binding sites 
for Zn (II) and Cu (II) 
(312, 313)
, and different metal binding modes of Aβ have been 
correlated to differences in the solubility of the complexes 
(312)
. It would be interesting to 
study the metal binding characteristics of an amyloidogenic LC protein.  
Other developments in MS may also facilitate the characterization of a LC/Ig 
protein. Different activation methods that generate different fragmentation mechanisms, 
such as the emerging large family of electron-activated dissociations (EXD), may provide 
additional dissociation products. These will offer complementary approaches to de novo 




(refer to the application of online ETD analysis in Chapter 2). They may also aid in PTM 
analysis, especially for labile modifications such as glycosylation, which can be 
important for a LC or an Ig. 
Mass spectrometers are now becoming essential tools for studies of Ig proteins. 
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